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I. Abstract 
The Raf/MEK/ERK pathway comprises a signaling network involved in vital cell 
processes such as proliferation, apoptosis and differentiation and is tightly linked 
to cancer development and maintenance. Raf, the entry point of the ERK cascade, 
is present in three different isoforms, A-, B-, and C-Raf, each with distinct bio-
logical functions. 
 
C-Raf is found over-expressed in a subset of human cancers, with particularly 
high frequency in hepatocellular carcinoma, the most frequently observed liver 
malignancy worldwide. Counterintuitively, hepatocyte-restricted ablation of the  
c-raf gene enhanced chemically-induced hepatocarcinogenesis in mice. This phe-
notype was rescued upon simultaneous c-raf ablation in hepatocytes and non-
parchenchymal liver cells (liver-restricted knock out), indicating that C-Raf has 
different, cell-type specific roles in chemically-induced liver carcinogenesis. The 
tumor suppressing effect of C-Raf observed in hepatocyte-restricted ablation was 
ascribed to its role in the initiation phase of tumor development, since not only 
tumor load but also tumor multiplicity was higher in hepatocyte-restricted c-raf 
knock out mice, indicating an elevated level of initiated cells, thus a higher initial 
susceptibility to chemical induced carcinogenesis. To gain insight in the differ-
ences between hepatocyte-restricted c-raf ablation and ablation in both parenchy-
mal and non parenchymal liver cells we compared the reaction of the animals 
immediately after the application of the carcinogen. These short-term experiments 
unveiled enhanced lipid droplet accumulation, prolonged STAT3 signaling and a 
delayed proliferative response in hepatocyte-restricted c-raf knock out mice. In 
the animals with c-raf ablation in liver parenchymal and non-parenchymal cells 
these effects could not be observed. Liver-restricted c-raf ablation was induced by 
the administration of Poly I:C, which triggered Cre recombinase expression and 
gene ablation, ten days prior to the induction of chemical carcinogenesis. Since 
Poly I:C induces an inflammatory state in the liver, and since inflammation is 
tightly interlinked with hepatocarcinogenesis, we sought to determine whether this 
treatment interfered with liver cancer development in our carcinogenesis protocol. 
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We could show that Poly I:C interfered with the induction of apoptosis and with 
the production pattern of the pro-tumorigenic cytokine IL-6 following carcinogen 
treatment in vivo. 
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II. Zusammenfassung 
Der Raf/MEK/ERK Signaltransduktionsweg ist ein essentielles Netzwerk, dass 
zur Informationsverarbeitung von der Zelle benutzt wird um lebenswichtige Pro-
zesse wie Wachstum, programmierten Zelltod und Zelldifferenzierung zu regulie-
ren und aufeinander abzustimmen. Diese Signalkaskade wurde in der Vergangen-
heit schon oft mit der Entstehung von Krebs assoziiert und ist Gegenstand derzei-
tiger Krebsforschung. Raf, die erste Kinase des ERK-Transduktionsweges, exi-
stiert in Säugetieren in drei verschiedenen Isoformen, A-, B- und C-Raf, wobei 
jede einzelne einer individuellen biologischen Funktion nachgeht.  
 
Im Rahmen der Entstehung bestimmter Karzinome wurde eine Überexprimierung 
von C-Raf festgestellt. Besonders im Zusammenhang mit dem hepatozellulärem 
Karzinom, dem weltweit häufigsten Lebermalignom, konnte eine aberrante Ex-
pression dieses Proteins nachgewiesen werden, was auf eine Funktion als Tumor-
promoter hinweist. Hepatozyten-spezifischer c-raf Knock-out in Mäusen in Ver-
bindung mit chemisch induzierter Karzinogenese wies eine tumorsupprimierende 
Wirkung von C-Raf auf, da c-raf Knock-out Mäuse eine erhöhte Inzidenz an Le-
bertumoren zeigten. Dieser Phenotyp konnte mit zeitgleicher Deletion von c-raf in 
Hepatozyten und nicht-parenchymalen Zellen (leber-spezifischer Kock-out) auf-
gehoben werden, was wiederum auf eine zelltypische Funktionsweise von C-Raf 
bei chemisch-induzierter Karzinogenese deutet.  
 
Der tumorsupprimierende Effekt von C-Raf im Hepatozyten-spezifischen Knock-
out scheint sich hauptsächlich in der Initiationsphase vom hepatozellulärem Kar-
zinom auszuwirken, da sowohl die Tumorgröße als auch die Tumormultiplizität in 
hepatozyten-spezifischen c-raf Knock-out Mäusen höher war. Dies erklärt sich 
durch eine erhöhte Suszeptibilität für chemisch induzierte Karzinogenese und so-
mit einer erhöhten Anzahl an initiierten Zellen. Um einen Einblick in die Unter-
schiede zwischen hepatozyten-spezifischem c-raf Knock-out und der Deletion von 
c-raf sowohl in Hepatozyten als auch in nicht-parenchymalen Zellen zu erhalten, 
wurde die Reaktion der Tiere sofort nach der Applikation des Karzinogens vergli-
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chen. Diese vergleichenden Analysen enthüllten eine erhöhte Akkumulation von 
Fetttröpfchen (Steatose), eine erhöhte und verlängerte STAT3 Signalwirkung und 
eine Verzögerung der proliferativen Antwort in der Leber kurz nach Applikation 
des Kanzerogens in hepatozyten-spezifischen Knock-out Mäusen. In den Tieren 
mit einer Deletion von c-raf in Hepatozyten und nicht-parenchymalen Zellen 
konnte dieser Effekte nicht beobachtet werden.  
 
Der leber-spezifischer c-raf Knock-out wurde durch die Injektion von Poly I:C 
induziert, womit die Expression der Cre Rekombinase und die Geneablation ein-
geleitet wurde, was 10 Tage vor der Applikation des Karzinogens statt fand. Poly 
I:C löst einen inflammatorischen Zustand in der Leber aus, und da Entzündung 
mit Hepatokarzinogenese zusammenhängt, versuchten wir eine mögliche Beein-
flussung des Karzinogeneseprotokolls durch diese vorangehende Poly I:C Be-
handlung festzustellen. Tatsächlich konnte nach der Karzinogenapplikation ein 
Effekt von Poly I:C auf die Apoptose und das Expressionsmuster von IL-6 nach-
gewiesen werden. 
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III. Introduction 
III.1 Cell signaling – We Need to Talk 
 
Processing information is central for every living organism, and thus also to their 
basic constituents, the cells. Communication systems have evolved to guarantee a 
successful exchange of information enabling a living together – not only for us 
humans, but also for cells which do communicate by producing, releasing and 
recognizing chemical molecules. This process, referred to as signaling, is used by 
cells to exchange information and coordinate their basic activities, as well as, in 
multi-cellular organisms, to direct and control process such as tissue homeostasis, 
development and immunity. Failure within these complex transmission routes 
leads to diseases such as cancer or autoimmunity. 
 
 
III.2 The MAPK paradigm 
 
The evolutionary conserved mitogen-activated protein kinase (MAPK) pathway is 
one of the most important signal transduction modules. Communication starts as a 
signal recognized at the cell surface, which is further transmitted to the nucleus or 
elsewhere in the cell, where it regulates vital processes such as proliferation, dif-
ferentiation, survival, apoptosis and cell motility. The general architecture of the 
MAPK pathway features a three-tiered cascade (Fig. 1A), composed of a MAPK 
kinase kinase (MAPKKK or MAP3K) typically activated by an upstream  
G-protein, which phosphorylates, thus activating, a MAPK kinase (MAPKK or 
MAPK2). The business end of the pathway, the MAPK, is phosphorylated by the 
MAP2K, and once activated phosphorylates numerous cytosolic and cytoskeletal 
substrates, thereby generating fast and transient changes in metabolism and cell-
shape. Further, durable changes can be triggered by translocation of activated 
MAPKs into the nucleus, where they interact with nuclear transcription factors to 
change gene expression pattern of the cell (Niault and Baccarini 2010). Inactiva-
tion of this cascade is achieved by dephosphorylation of these three kinases via 
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specific phosphatases, referred to as MAPK phosphatases (Chang and Karin 2001; 
Baccarini 2005; Orton et al. 2005; Niault and Baccarini 2010).  
 
The MAPK signaling system is capable of amplifying the signal at each stage. In 
addition, parameters such as kinetics, duration and amplitude of activity can be 
regulated separately for each tier (Kolch 2000). It is important to mention that 
MAPK pathways, although originally described as linear and unidirectional, are 
competent to interact with members of other pathways through kinase-dependent 
and/or kinase-independent functions (Hindley and Kolch 2002; Baccarini 2005). 
These processes are referred to as signal cross talk.  
 
To date, four functionally distinct MAPK pathways have been elucidated with 
four terminal MAPKs, which are eponymous for these cascades: extracellular 
signal regulated kinase (ERK-1/2), Jun amino-terminal kinases (JNK-1/2/3), p38 
(α/β/γ/δ) and ERK5 (Chang and Karin 2001). Each of these MAPKs can be acti-
vated not only by one MAP2K, but rather by diverse MAP2Ks, and that this 
scheme applies also on the level of MAP3Ks, clearly illustrates the intrinsic com-
plexity of this signal transduction paradigm. 
 
 
III.3 The Raf/MEK/ERK pathway 
 
The ERK pathway was one of the first pathways to be described, providing a 
roadmap for signals coming from the cell surface and being transduced to the nu-
cleus. This pathway has been extensively studied and features Raf (rapidly grow-
ing fibrosarcoma) as MAP3K, MEK (MAPK and ERK kinase) as MAP2K and 
finally ERK as MAPK (Fig. 1B). Extracellular signals trigger this pathway by 
activating growth factor receptors (receptor tyrosine kinases - RTKs), leading to 
the assembly of receptor cell signaling complexes including the adaptor proteins 
Grb (growth factor receptor bound protein) 2 and Shc (Src homology and collagen 
homology). Through the activation of SOS (son of sevenless), a GDP/GTP ex-
change factor (GEF), and the subsequent exchange of Ras-bound GDP with GTP, 
the small GTPase Ras (rat sarcoma) changes into its active confirmation, thus 
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recruiting Raf to the inner cell membrane. Raf is activated by direct interactions 
with Ras and by a rather complex, not fully understood process including phos-
phorylation, dephosphorylation and changes in conformation. Further down the 
pathway, activated Raf phosphorylates its downstream target MEK, which will in 
turn phosphorylate ERK (Orton et al. 2005). This terminal MAPK has at least 180 
known substrates in nucleus and cytoplasm (Yoon and Seger 2006) making it the 
kinase with the largest assortment of effectors (Niault and Baccarini 2010). The 
ERK pathway is attenuated after activation by negative feedback loops imple-
mented by ERK and shut down by sequential dephosphorylation of activating 
residues on Raf, MEK and ERK (Niault and Baccarini 2010). 
 
Mammals have two distinct erk genes (erk 1/2), two mek genes (mek 1/2) and 
three raf genes (a-, b- and c-raf also c-raf-1). Each level of the ERK pathway con-
sists of more than one component, accounting for increased flexibility via hetero- 
and homodimerization and individual biological functions. C-Raf and B-Raf form 
heterodimers upon Ras activation, resulting in a higher MEK kinase activity com-
pared to the single constituents or homodimers (Weber et al. 2001; Garnett et al. 
2005; Rushworth et al. 2006). Further, MEK1 and MEK2 heterodimers are sig-
nificantly involved in the fine tuning of the pathway (Catalanotti et al. 2009), and 
ERK homodimers are important for spatial specificity (Casar et al. 2008). 
- 16 - 
 
Figure 1. The MAPK Pathway and the Raf/MEK/ERK pathway, adapted form (Niault and 
Baccarini 2010)  
A) The MAPK pathway: general assembly of a three-tiered MAPK cascade including 
the three kinases MAP3K, MAP2K and MAPK. Upon activation each kinase passes the 
signal on to its downstream target via phosphorylation (P for phosphate group). The ac-
tivated MAPK triggers short-lived changes by phosphorylation of cytosolic substrates 
and long-lived changes by phosphorylation of nuclear targets influencing gene expres-
sion. B) The Raf/MEK/ERK pathway: upon receptor stimulation by growth factors and 
hormones, the Raf/MEK/ERK cascade initiates and proceeds towards its business end 
ERK. Adaptor proteins (Grb2, Shc) recruit the GDP/GTP exchange factor SOS, which 
in turn activates the small GTPase Ras. Raf becomes then activated by Ras, transmitting 
the signal by phosphorylation further to its downstream target MEK. Activated MEK 
phosphorylates ERK, rendering it able to activate its various substrates. B-Raf has been 
shown to be the most potent MEK activator, as is illustrated by the thickness of the ar-
rows. 
 
 
The distinct biological functions of kinases belonging to the same tier of the cas-
cade are illustrated best by the example of the MAP3Ks A-Raf, B-Raf and C-Raf. 
All three Raf isoforms feature a common structure with three conserved regions 
(CR1, CR2, CR3) (Fig. 2). CR1 and CR2, both part of the regulatory domain, are 
located in the N-terminus, whereas CR3, harboring the kinase domain, is located 
in the C-terminus. CR1 consists of a Ras-binding site (Galabova-Kovacs et al.) 
and a cystein-rich domain (CRD), which are needed for membrane recruitment 
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(Ras binding site) and autoinhibition (CRD). CR2 features a multitude of negative 
regulatory phosphorylation sites, including a negative regulatory serine residue 
(Wellbrock et al. 2004; Niault and Baccarini 2010). Considering these structural 
and functional similarities, one could be misled into believing that the three Raf 
proteins are functionally redundant. Instead, biochemical and in vivo studies (in-
cluding knock-in and knock-out experiments) proved that each individual isoform 
has essential biological functions.  
 
 
 
 
B-Raf is considered to be the main MEK activator, as its Ras binding and kinase 
activity were shown to be stronger than in the two other Raf isoforms (Pritchard et 
al. 1995; Marais et al. 1997; Galabova-Kovacs et al. 2006; Sobczak et al. 2008). 
The conventional ablation of B-Raf led to embryonic lethality around midgesta-
tion, as a result of reduced vascular development in the placenta. Deletion of  
B-Raf in the embryo itself (ablation in the epiblast compartment) yielded viable 
offspring, which died around three weeks after birth because of neurological de-
fects (Galabova-Kovacs et al. 2006).  
 
Conditional ablation of B-Raf (for details about knockout models see below) in 
several tissues and cell types e.g. in brain, where B-Raf is preferentially expressed 
(Chen et al. 2006; Galabova-Kovacs et al. 2008), thymocytes (Tsukamoto et al. 
2008) and endothelial cells (Wimmer et al., unpublished data) leads to tissue-
specific phenotypes, including decreased MEK and ERK phosphorylation and 
Figure 2. Structure of Raf isoforms,  
adapted from (Thiel et al. 2009) 
A-, B- and Raf-1 (C-Raf) share three con-
served regions: CR1 containing a cysteine 
rich domain and Ras-binding sub-domain for 
Ras-GTP binding, CR2 with numerous serine 
and threonine residues influencing the cata-
lytic activity and CR3 harboring the kinase 
domain. 
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therefore attenuation of signal processing through the ERK pathway, reinforcing 
B-Raf’s status as main activator of MEK (Niault 2009). 
 
Conventional c-raf ablation results, as the b-raf deletion, in embryonic lethality 
during midgestation. Embryos lacking c-raf are retarded in growth, display vascu-
larization defects in placenta and the yolk sac, and show increased apoptosis espe-
cially in the fetal liver, while proliferation was unchanged (Huser et al. 2001; 
Mikula et al. 2001). These results showed that C-Raf is essential for preventing 
apoptosis rather than for promoting proliferation (Piazzolla et al. 2005), thereby 
breaking new ground within this signaling pathway.  
 
Conditional c-raf knockouts and biochemical studies led to deeper understanding, 
revealing kinase-independent functions of C-Raf and providing new insights into 
its function in pathway cross-talk. Two pro-apoptotic kinases were identified so 
far as C-Raf interaction partners: mammalian sterile 20 (Ste20)-like protein kinase 
2 (MST2), involved in the regulation of the Lats/YAP pathway (O'Neill et al. 
2004), and apoptosis signal-regulating kinase 1 (ASK1), regulating apoptosis 
triggerd by death receptors or stress, functioning upstream of JNK and p38 (Chen 
et al. 2001; Yamaguchi et al. 2004; Baccarini 2005). Both kinases, ASK1 and 
MST2, are inhibited through a kinase independent mechanism, involving com-
plex-formation with C-Raf and inhibiting/modulating the target’s kinase activity. 
Last but not least a third kinase, Rho kinase α (Rok-α), was brought to light as a 
C-Raf interaction partner. Rok-α is a cytoskeleton-based kinase engaged in migra-
tion, thereby influencing cell shape and motility (Baccarini 2005). 
 
In contrast to B-Raf and C-Raf, A-Raf has been the less extensively studied 
MAP3K of the ERK pathway. Conventional knockout of the a-raf gene does not 
result in embryonic lethality. a-raf deficient mice are born normal but fail to 
thrive and die between P7 (post partum) and P21 displaying neurological and in-
testinal abnormalities. Depending on the genetic background, mice lacking the  
a-raf gene can also survive the adolescence and grow up with minor neurological 
defects (Pritchard et al. 1996). Thus, A-Raf is not required for embryonic devel-
opment, yet it is possibly indispensible after birth. 
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Taken together, the Raf kinase family illustrates in an impressive manner that 
each protein has its own distinct and indispensable functions. In addition, expres-
sion of the three isoforms varies from tissue to tissue and localization within the 
cell differs (Barnier et al. 1995; Morice et al. 1999; Wojnowski et al. 2000) dem-
onstrating again how complex and tunable MAPK pathways are. 
 
 
III.4 Signaling Pathways and Cancer – Focusing on Ras and 
Raf 
 
The term ”cancer”, defining diseases where a cluster of cells behave aberrantly, 
proliferating uncontrollably, invading surrounding tissue and in certain cases me-
tastasizing to different regions of the body, was probably first introduced in 
Greece more than 2000 years ago by Hippocrates. Since then, knowledge about 
this class of diseases has grown continuously, especially in the last 35 years dur-
ing which genetic alterations connected to cancer were identified (Graves 2000). 
In 2000, Hanahan and Weinberg published their famous review ‘Hallmarks of 
Cancer’ combining and integrating the plethora of information gathered up to that 
point and outlining the main features of cancer: cell-sufficiency in growth signals, 
evading apoptosis, insensitivity to anti-growth signals, limitless replicative poten-
tial, sustained angiogenesis, metastasis and tissue-invasion (Hanahan and 
Weinberg 2000). All these hallmarks are reflections of aberrant signaling by 
pathways controlling proliferation, apoptosis, differentiation and motility (Martin 
2003). MAPK pathways have been shown to be almost indispensible for tumor 
formation, as numerous cancer types harbor mutations resulting in over-activation 
of the pathway and/or over-expression of its components (Ding et al. 2007). 
 
Within the ERK pathway, ras and b-raf are the two genes most susceptible to ac-
tivating mutations. With an average incidence of 33% in all human cancers, ras is 
the oncogene most frequently found mutated. These mutations are mostly local-
ized to the Ras GTPase region and retain Ras in its active state, driving its down-
stream pathway continuously. b-raf mutations enhance predominantly the kinase 
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activity towards its sole substrate MEK, resulting again in increased ERK signal-
ing. Less common mutations lower B-Raf kinase activity but increase its ability to 
form heterodimers with C-Raf, ultimately stimulating C-Raf’s kinase activity and 
therefore the MEK/ERK pathway (Davies et al. 2002; Garnett et al. 2005; Niault 
and Baccarini 2010). 
 
C-Raf is rarely mutated but is an aberrantly expressed protein present in a subset 
of different cancers. Over-expression of C-Raf is frequently observed in 
squamous cell carcinomas (Riva et al. 1995), lung adenocarcinomas (Cekanova et 
al. 2007) and hepatocellular carcinomas (Huynh et al. 2003; Hwang et al. 2004). 
Furthermore, C-Raf has been found to be essential for development and mainte-
nance in Ras-driven skin tumors by inhibiting Rok-α through its kinase-
independent functions (Ehrenreiter et al. 2009). The effect on several pathways 
simultaneously and the associated interference with processes such as differentia-
tion and proliferation is evident, considering C-Raf’s ability in cross-talking and 
its numbers of downstream targets, resulting finally in contribution to tumor de-
velopment. 
 
 
III.5 The Murine Liver: Hepatocelluar Carcinoma and  
c-raf – Vicious Love Birdies 
 
The liver is the largest gland and the central metabolic organ of the body. Detoxi-
fication, glycogen storage, protein synthesis and hormone production are pivotal 
functions accomplished by this organ. Furthermore, the liver is responsible for 
bile production, an adjuvant in the digestion process. Anatomically, the liver is 
divided into lobes, the number of which varies among species. In rodents, the liver 
comprises one large and three smaller lobes.  
 
Blood flow through the liver is essential for both oxygen supply and for its meta-
bolic functions. Nutrient-enriched blood coming from the gastrointestinal tract 
(and to a considerably lower extent from spleen and pancreas) enters the liver 
through the vena portae (portal vein), whose numerous branches create a complex 
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vascular system (Fig 3A). Following the flow, the blood exits the portal veins into 
intrahepatic spaces, the sinusoids, collects again in the central veins and leaves the 
liver through the vena hepaticae (hepatic vein). A second vascular system, start-
ing with the arteria hepatica propria (hepatic artery proper) and branching into 
hepatic arteries, runs through the liver ensuring the supply of oxygen and nutrients 
for the organ itself. Hepatic arteries are found next to portal veins, together with a 
bile duct, forming the portal triads. The basic structural unit of the liver is called 
lobule, not to be confounded with anatomical lobes, and comprises a central vein 
surrounded by six portal triads (Fig. 3B). 
 
 
 
Figure 3. Hepatic vascular system and hepatic lobule, adapted from John Hopkins Medicine 
(www.hopkins-gi.org/Upload/200710290953_38845_000.jpg) 
A) A schematic depiction of the hepatic blood supply system including the hepatic por-
tal vein, the hepatic artery and the common bile duct. B) A schematic picture of the he-
patic lobule with one central vein being surrounded by 6 portal triads. Blood flow (blue 
and red vessels) and bile flow (green vessels) are indicated by black arrows in both im-
ages. 
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Two portal triads and a central vein form a triangle referred to as acinus, which is 
considered the functional unit of the liver (Fig. 4). In the acinus, blood from the 
portal vein circulates into sinusoids, which are capillary-like blood vessels lined 
with interrupted endothelium containing the liver resident macrophages or 
Kupffer cells. Through gaps in the endothelium, termed fenestrae, blood seeps out 
of the sinusoids deeper into the tissue, the so-called Space of Disse. There it 
reaches the parenchymal cells of the liver, the hepatocytes, which take up and 
metabolize oxygen, nutrients and toxins.  
 
Figure 4. Structure of the liver acinus and sinusoids, adapted from (Adams and Eksteen 
2006) 
Portal veins and hepatic arteries ensure the blood supply of the liver. Blood from these 
vessels reaches the sinusoids, proceeds along the acinus and collects in the central vein. 
Sinusoids (depicted on the right) are small vessels lined with specific endothelial cells 
that have a unique morphology and phenotype. These cells are characterized by fenes-
trae (small interruptions of the endothelium) and the absence of tight junctions. The 
macrophages of the liver (Kupffer cells) reside in the sinusoids. The Space of Disse lies 
between the sinusoidal endothelium and the hepatocytes and hosts Ito cells (hepatic stel-
late cells) that store fat and vitamins, and dendritic cells. 
 
As the main detoxifying organ of the body, the liver is confronted with metabolic 
and oxidative stress as well as immunological responses to pathogens on a regular 
basis. But since the dose makes the poison, chronic inflammation and excessive 
liver damage, triggered by various causes such as immoderate alcohol consump-
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tion and hepatitis, can result in a variety of diseases such as steatosis, cirrhosis and 
cancer.  
 
The most frequent primary liver disease worldwide is hepatocellular carcinoma 
(HCC), taking a toll of over 610.000 deaths per year (WHO 2009). Once HCC has 
been diagnosed, prognosis is very poor, enlisting this type of cancer among the 
top three of most lethal cancers (Parkin et al. 2001). The main reasons for this are 
late diagnosis and lack of effective treatments. Early HCC is hardly recognized 
since this disease is almost asymptotic and screening methods are unsatisfactory 
(Thomas and Abbruzzese 2005). In addition, treatment of HCC so far has very 
low success rates, due to the lack of effective therapeutics for patients suffering 
from advanced HCC (Whittaker et al. 2010).  
 
Pathogenesis of HCC is complex involving on the one hand cirrhosis as a conse-
quence of sustained tissue damage and on the other hand mutations in oncogenes 
and/or tumor suppressors. Cirrhosis is caused by infections (hepatitis), metabolic 
defects (e.g.: non-alcoholic steatohepatitis (NASH), obesity and type II diabetes) 
and toxins (e.g.: alcohol or aflotoxin B) and is characterized by fibrosis (replace-
ment of parenchyma by connective tissue) and regenerative nodules (Whittaker et 
al. 2010). Several signaling networks – growth factor mediated signaling, MAPK 
pathways, AKT and WNT signaling, to name a few – have been closely associ-
ated with cirrhosis and HCC.  
 
The RAF/MEK/ERK pathway is at the center of our interest since it has been 
proven to be constitutively active in HCC, with increased MEK 1/2 and ERK 
phosphorylation in tumor tissue compared to non-effected tissue (Ito et al. 1998; 
Huynh et al. 2003; Hwang et al. 2004). This seems to be dependent on two main 
mechanisms: activating ras mutations and constitutive activation of C-Raf by de-
regulated growth factor expression. Activating ras mutations have been found in 
HCC, percentages depending on the source varying from 4% (Catalog of Somatic 
Mutations in Cancer) to 30% (Whittaker et al. 2010). Furthermore, over-
expression of c-raf has been found in 100% of human HCC samples (30 speci-
mens analyzed by Hwang et al, 2004). In contrast, b-raf mutations seem to be 
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very rare in HCC (Tannapfel et al. 2003), which is particularly interesting because  
b-raf mutations are commonly observed in many other cancer types.  
 
 
III.6 Inflammation, Regeneration and Liver Cancer – Kupffer 
Cells as Key Players 
 
The relationship between cancer development and inflammation has been 
recognized since the nineteenth century. HCC is a prime example for an inflam-
mation-associated cancer type, since chronic inflammation is invariably associ-
ated with this malignancy (Berasain et al. 2009). Hepatic inflammation is medi-
ated mainly via Kupffer cells, which react to inflammatory stimuli. These liver 
resident macrophages derive from circulating monocytes, which develop out of 
progenitors from the bone marrow and differentiate into Kupffer cells when local-
izing to the liver. Apart from phagocytosis and antigen processing and presenting, 
Kupffer cells produce and release inflammatory mediators, reactive oxygen spe-
cies and growth factors, which in turn influence endothelial cells, stellate cells and 
most importantly hepatocytes (Stienstra et al. 2010).  
 
The interplay between Kupffer cells and hepatocytes has not yet been fully clari-
fied, but two different scenarios have been proposed. The first involves Kupffer 
cells as primary responder to toxic signals, leading to the release of cytokines, 
which affect hepatocyte proliferation, survival and function. In some cases the 
activation of Kupffer cells has been shown to protect, yet in others to damage the 
parenchyma (Roberts et al. 2007). Roberts et al. (2007) hypothesized that the pri-
mary Kupffer cell response can shift from protective to damaging during pro-
longed inflammation (threshold hypothesis). In the second scenario the hepato-
cytes send signals forth to Kupffer cells, which in turn support hepatocyte survival 
and protect from apoptosis.  
 
Hepatic inflammation entails liver damage, which is followed by liver regenera-
tion. This process is based on the production of cytokines such as interleukin (IL) 
6 and tumor necrosis factor (TNF) α, and of growth factors such as hepatocyte 
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growth factor (HGF), transforming growth factors (TGFs) and epidermal growth 
factor (EGF) (Taub 2004).  
 
IL-6 and TNF-α are crucial for liver regeneration (Fig. 5). By activating the tran-
scription factor nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB), TNF-α stimulates Kupffer cells to produce IL-6. Secreted IL-6 is recog-
nized by hepatocytes through the corresponding IL-6 Receptor (IL-6R) initiating a 
cascade including association of two gp130 and activation of two Janus kinases 
(JAKs), cross-phosphorylation of JAKs and phosphorylation of signal transducer 
and activator of transcription (Stat) 3. Activated Stat3 dimerizes and translocates 
to the nucleus, where it activates genes involved in the so-called acute phase re-
sponse (elimination of toxic or infectious agents), in liver regeneration and in he-
patoprotection (protection against chronic liver injury). A second pathway acti-
vated by IL-6 is the MAPK pathway (especially ERK and JNK), considered vital 
for hepatocyte proliferation (Taub 2004). 
 
 
 
Figure 5. Stat3 signaling in liver regeneration, adapted from (Taub 2004) 
TNF-α is recognized by KCs, which in turn activate NF-κB thereby triggering IL-6 ex-
pression. IL-6 binds to IL-6R resulting in the activation of JAKs. JAKs phosphorylate 
(P for phosphate group) Tyrosine residues on Stat3, which dimerizes and translocates to 
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the nucleus where it upregulates the transcription of immediate-early genes, thereby 
triggering the acute-phase response, hepatoprotection and liver regeneration. The sec-
ond pathway activated through IL-6 is the MAPK pathway – for details see Fig. 1. 
 
IL-6 is important in the acute phase response and hepatoprotection, but is not by 
itself sufficient to induce the process of liver regeneration (Cressman et al. 1996; 
Sakamoto et al. 1999). Growth factor-driven pathways stimulate the proliferative 
response upon liver injury, thereby supporting restoration and maintenance of 
liver function and architecture. HGF and TGF-α are regarded as the two most 
important growth factors in liver regeneration. Both growth factors are involved in 
activation of mitogenic pathways such as PI3K, ERK and AKT, and stimulate 
DNA synthesis and proliferation (Taub 2004). 
 
 
III.7 Conditional Knock Out Systems 
 
Conventional c-raf ablation results in embryonic lethality. Therefore, we use a 
conditional knock out system to target a particular cell type (tissue-restricted abla-
tion) and/or a specific point in time (temporally controlled ablation). To achieve 
this, we use the site-specific Cre recombinase (Type I topoisomerase) from bacte-
riophage P1. The Cre recombinase recognizes and cuts specific DNA sequences, 
so called LoxP sites, resulting in the excision of the intervening sequences. If the 
LoxP sites are placed in introns flanking an essential exon, this causes the disrup-
tion of the floxed (flanked by Lox) gene (Fig. 6). The expression of the Cre re-
combinase is typically controlled by a tissue-restricted or by an inducible pro-
moter (Rajewsky et al. 1996).  
 
Several promoter systems are available for liver-restricted gene ablation. In this 
study, we used the Alfp promoter and the Mx1 promoter. The Alfp promoter de-
rives from the albumin promoter (Alb) and consists of the mouse albumin enhan-
cer, the albumin promoter and an α-fetoprotein enhancer. In Alfp-Cre transgenic 
mice recombinase expression starts around embryonic day (E) 10.5 and excision 
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of floxed DNA is observed specifically in hepatocytes and biliary epithelia cells 
(Kellendonk et al. 2000; Metzger 2004). 
  
The Mx1 promoter is induced by interferons and is therefore activated in inter-
feron sensitive cells, affecting a larger spectrum of cells than the Alfp promoter 
system. In Mx-Cre mice Cre expression is triggered via intra peritoneal (i.p.) in-
jection of either interferon itself or PolyI:PolyC (double stranded RNA polymer), 
which induces interferon production by peritoneal macrophages. Ablation of 
floxed DNA segments is detected in liver to almost 100%, not only in hepatocytes 
but also in non-parenchymal cells such as hepatic stellate cells and Kupffer cells. 
Even though other tissues are also affected (to a lesser extent), this knock out 
model has been instrumental in elucidating gene functions in the liver (Kuhn et al. 
1995; Metzger 2004).  
 
Transgenic mice harboring the Cre recombinase are mated to animals carrying the 
floxed alleles of interest to generate a conditional knock-out line. In this study, we 
used a c-raf flox mouse line [c-raf F/F], crossed to either the Alfp-Cre or the  
Mx-Cre mouse line, resulting in [c-rafΔhep/Δhep; Alfp-Cre] or [c-raf F/F; Mx-Cre], 
respectively. [c-rafΔliv/Δliv; Mx-Cre] animals are obtained by Poly I:C application, 
which activates the transcription of the Cre gene. Efficient ablation of c-raf is 
achieved through Cre-mediated excision of exon 3.  
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 cell with active promoter: cell with inactive promoter: 
 
  
 
Figure 6. The Cre-LoxP-system  
Upon activation of a specific promoter (either tissue specific or inducible) Cre recom-
binase is expressed and excises DNA flanked by two LoxP sites (marked by a black tri-
angle). Excision of c-raf exon 3 creates a tissue-restricted or temporally-restricted gene 
knock out. 
 
 
III.8 Tumor Model 
 
Chemically-induced carcinogenesis has been extensively used to study all kinds of 
cancer types in rodents. One important paradigm emerging from these data is that 
carcinogenesis comprises three stages: initiation, promotion and progression (Fig. 
7). Every cancer is believed to start with a single hit predisposing a normal cell to 
a malign development. This first step is categorized as initiation and is linked with 
irreversible changes in the genome of the affected cell. Promotion, the second 
stage, is marked by growth stimuli induced by tumor promoters, which enhance 
proliferation of susceptible cells. Upon withdrawal of tumor promoters, prolifera-
tion can normalize and newly formed neoplasias may regress (most likely through 
apoptosis), making promotion a reversible process. The last stage, progression, is 
completely irreversible. Neoplasias and pre-neoplastic lesions transform into ma-
lignant lesions in which proliferation is entirely independent of promoting agents. 
The hallmarks of these lesions are uncontrolled growth, genomic instability, inva-
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sion and metastasis (Oliveira et al. 2007). Although it represents an oversimplifi-
cation, this three-staged model is widely accepted as a working model. 
 
 
Figure 7. Three stage carcinogenesis model, adapted from (Oliveira et al. 2007) 
Genotoxic chemical compounds initiate cells, which become malignant via promotion 
and progression and finally invade into neighboring tissue. It is important to note that 
promotion is a reversible step, whereas progression is irreversible. 
 
 
N-Nitrosodiethylamine (NDEA) also called diethylnitrosamine or shortly DEN is 
frequently used to induce hepatocarcinogenesis in laboratory animals. DEN is 
classified as ‘probable human carcinogen’ by the International Agency for Re-
search on Cancer review (IARC) and is found in tobacco smoke, meat and whis-
key (Verna et al. 1996). Apart from inducing cancer in the liver of rodents, cancer 
development could also be detected in the skin, the respiratory tract, and the gas-
trointestinal tract (Park et al. 2009). Genetic analysis of gene expression patterns 
showed that in DEN-induced experimental tumors gene expression is similar to 
that of HCC patients with poorer survival rate, validating DEN-induced carcino-
genesis as an accurate HCC model (Lee et al. 2004).  
 
DEN itself is not excretable and needs to undergo biotransformation (Fig. 8) to 
unfold its genotoxic character (Verna et al. 1996). Biotransformation of DEN in 
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the liver involves CYP2E1, a member of the cytochrome P450 system (CYP). 
CYP2E1 initiates bioactivation of DEN via oxygen- and NADPH-dependent hy-
droxylation, leading to the production of α-hydroxyl-nitrosamine (Kang et al. 
2007). This first activation step occurs mostly in pericentral hepatocytes, in which 
the enzymatic activity of CYP2E1 is highest. α-Hydroxyl-nitrosamine is further 
processed to an ethyl-diazonium ion (electrophilic) by cleavage of an acetalde-
hyde group. DNA damage results from the alkylation of nucleophilic DNA-bases 
by the electrophilic ethyl-diazonium ion (Heindryckx et al. 2009). In addition to 
its genotoxicity, DEN causes oxidative stress via the CYP system, which gener-
ates reactive oxygen species (ROS), further contributing to cancer development 
(Heindryckx et al. 2009).  
 
 
 
 
 
DEN-induce HCC development is not only dose-dependent but also age-, sex- and 
strain-dependent (Rao and Vesselinovitch 1973). Because of high hepatic prolif-
eration rates in young animals, HCC develops much faster in these than in older 
ones (Vesselinovitch and Mihailovich 1983). Interestingly, HCC incidence upon 
DEN treatment differs drastically from males to females. Whereas 100% of DEN-
treated male mice develop HCC, only 30% of treated females are affected 
(Nakatani et al. 2001). Considering that the lion’s share of patients suffering from 
liver cancer is male, the pivotal question of gender-specific defense against car-
cinogens comes up. Estrogens were shown to have an inhibitory effect on HCC 
Figure 8. Biotransformation 
of DEN, adopted from (Verna 
et al. 1996) 
DEN is hydroxylated by 
CYP2E1 to α-hydroxyl-nitro-
samine and further processed to 
yield an ethyl-diazonium ion 
upon cleavage of acetaldehyde. 
The electrophilic ethyl-
diazonium ion can alkylate 
DNA, thereby causing the for-
mation of DNA adducts. 
DEN 
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development, thus rendering females less susceptible to HCC (Nakatani et al. 
2001; Naugler et al. 2007). Further, strain-related differences in DEN-induced 
carcinogenesis were observed, originating from different methylation patterns 
dividing mouse strains into tumor sensitive and tumor insensitive strains 
(Buchmann et al. 1991).  
 
DEN is often used in a combined two-step carcinogenesis system, in which a sin-
gle application is followed by treatment with a promoting agent (e.g. Phenobarbi-
tal; Pb) administered over weeks or even months. The tumor-promoting character-
istics of Pb have not been fully clarified, but they include the capability to influ-
ence the expression of CYP and enhancing oxidative stress (Waxman and Azaroff 
1992; Watson and Goodman 2002; Imaoka et al. 2004). Pb treatment has been 
connected with alterations in proliferation through interaction with intracellular 
signaling networks and changes in the methylation of tumor suppressor genes 
(Heindryckx et al. 2009).  
 
 
III.9 To Date: c-raf Deletion Promotes HCC Development and 
Progression in c-rafΔhep/Δhep Mice but not in  
c-rafΔliv/Δliv Mice (unpublished data, Maurer et al.) 
 
Since C-Raf has been shown to be frequently over-expressed in HCC, and Soraf-
enib, an in vivo c-raf inhibitor (amongst others), is currently the only successful 
therapeutic approach in liver cancer treatment, studies on C-Raf in liver cancer 
development are indispensible. We generated conditional c-raf knock out mice 
using the Cre-LoxP system (see above) and induced HCC by a two-step carcino-
genesis protocol. A single DEN application (i.p.) was administered to four weeks-
old male mice, followed four weeks later by a promotion period in which they 
were fed Pb-supplemented diet. Wild-type controls as well as c-raf knock out 
mice developed HCC within 26-30 weeks upon treatment.  
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The two Cre transgenic lines described above were used to achieve conditional  
c-raf ablation. DEN/Pb-treated c-rafΔhep/Δhep animals displayed a significant in-
crease in liver/body weight ratio, tumor number and tumor occupied area, when 
compared to c-raf F/F control animals. These results contradicted the expectations 
raised by the analysis of C-Raf expression in human HCC, since the knock out of 
a protein found over-expressed in HCC would be predicted to reduce cancer de-
velopment. Apparently, disturbance of the ERK pathway and/or the pathways 
influenced by the kinase-independent function of C-Raf renders the liver more 
sensitive to tumor formation. Furthermore, mitotic and apoptotic indexes were 
similar in tumor-bearing c-rafΔhep/Δhep and c-raf F/F livers, thus suggesting that  
C-Raf plays a role in early HCC development, most probably during initiation. 
Therefore, we chose to analyze the events taking place shortly after DEN applica-
tion. The analysis of proliferation showed a delay in c-rafΔhep/Δhep compared to  
c-raf F/F livers, but no difference in apoptosis could be detected. In addition, DEN-
induced STAT3 activation was prolonged and further lipid droplet accumulation 
was increased in c-rafΔhep/Δhep livers. In contrast, enhanced tumorigenesis could not 
be observed in c-rafΔliv/Δliv compared to c-raf F/F animals treated with Poly I:C 30 
weeks after DEN/Pb treatment but c-rafΔliv/Δliv as well as c-raf F/F mice treated with 
Poly I:C displayed both in general more tumorigenesis when compared to c-raf F/F 
not treated with Poly I:C 
 
At least two explanations can be put forward to interpret these findings: firstly, 
and most likely, the reason for the differences in c-rafΔhep/Δhep and rafΔliv/Δliv animals 
is determined by the cell types affected by the knock out (parenchymal cells only 
in c-rafΔhep/Δhep; and parenchymal/non-parenchymal cells, particularly Kupffer 
cells, in c-rafΔliv/Δliv mice); and secondly, the difference may stem from the pro-
inflammatory Poly I:C treatment used to ablate c-raf in c-rafΔliv/Δliv. Distinguishing 
between these two possibilities is the aim of this thesis. 
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IV. Results 
IV.1 Liver-restricted c-raf Ablation 
 
Conventional knock out of c-raf results in embryonic lethality, which correlates 
with increased fetal liver apoptosis (Mikula et al., 2001). Therefore, the condi-
tional knock out system Cre/loxP was used to generate liver-restricted gene abla-
tion. c-raf ablation in liver was detected by conventional PCR, which illustrated 
the conversion of floxed alleles (F) into deleted alleles (Δhep and Δliv) of c-raf (Fig. 9 
A). Further, immunoblotting was used to verify the absence of C-Raf protein in 
liver tissue (Fig. 9B).  
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Figure 9. Liver Specific c-raf Ablation. 
A) PCR analysis: administration of Poly 
I:C triggers Cre expression, which in 
turn excises exon 3 of the floxed c-raf 
gene, resulting in the amplification of the 
Δ allele. A c-raf F/Δ sample served as 
PCR control, to verify that both bands 
were amplified with a similar efficiency. 
B) Western blot for detection of C-Raf 
proteins in liver tissue. Deletion was 
efficient, since almost no C-Raf protein 
was detectable (residual protein may 
result from the inclusion of cells not 
affected by Poly I:C, e.g. endothelial 
cells). 
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Long-term effects of DEN treatment on c-rafΔhep/Δhep and c-rafΔliv/Δliv mice were ana-
lyzed by Maurer et al. (unpublished data). Increased susceptibility to tumor for-
mation was found in c-rafΔhep/Δhep but not in c-rafΔliv/Δliv mice. The early effects after 
drug-induced liver injury in hepatocytes-restricted c-raf ablation compared to 
those of the simultaneous deletion in hepatocytes and non-parenchymal cells was 
central to this study. Maurer et al. further found accelerated liver cancer develop-
ment in Poly I:C treated animals, which is needed for activation of Cre expression 
in c-rafΔliv/Δliv mice, suggesting a tumor promoting effect of this agent. In order to 
discriminate between the consequences of the different ablation patterns in  
c-rafΔhep/Δhep and c-rafΔliv/Δliv mice, and those of the Poly I:C administration in  
c-rafΔliv/Δliv, we treated  c-rafΔhep/Δhep animals with Poly I:C prior to DEN exposure 
and compared them directly to DEN-exposed c-rafΔliv/Δliv mice.  
 
C-Raf, although not considered as the prime kinase actvating ERK, is in principle 
capable of driving this pathway. Therefore, c-raf ablation might negatively 
impinge on the levels of phosphorylated ERK. However, in Poly I:C-treated c-raf 
knock out mice (both c-rafΔliv/Δliv and c-rafΔhep/Δhep) ERK activation was slightly ele-
vated when compared to c-raf F/F littermates (Fig. 10 A-B). pERK levels equal-
ized after DEN treatment in c-rafΔliv/Δliv compared to their Poly I:C treated wildtype 
controls (Fig. 10 A). By contrast, in livers of c-rafΔhep/Δhep mice ERK signaling re-
duced at 48h after DEN treatment when compared to their c-raf F/F littermates 
(Fig. 10 B).  
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Figure 10. Western blot Analysis of ERK Activation in c-raf F/F, c-rafΔliv/Δliv and  c-rafΔhep/Δhep  
Mice treated with Poly I:C at 0h, 24h and 48h. 
A) pERK immunoblot of liver lysates from Poly I:C injected c-raf F/F and c-rafΔliv/Δliv 
animals treated with DEN for 0h, 24h and 48h. B) pERK immunoblot of liver lysates 
from c-raf F/F and c-rafΔhep/Δhep animals treated with DEN for 0h, 24h and 48h. pERK 
levels are higher in untreated c-rafΔliv/Δliv and c-rafΔhep/Δhep animals treated with Poly I:C 
than in c-raf F/F or c-rafF/F littermates. This difference disappears upon DEN treatment 
(24h and 48h) in c-rafΔliv/Δliv mice (A). c-rafΔhep/Δhep animals showed a small reduction of 
ERK signaling 48h after DEN treatment (B). 
 
Comparison of Liver Injury upon DEN treatment in Poly 
I:C-treated c-raf F/F, c-rafΔliv/Δliv and c-rafΔhep/Δhep mice 
 
DEN is a genotoxic agent, which induces damage and morphological changes in 
the liver. 24 hours after DEN application, macroscopic changes became visible as 
clear spots all over the liver of Poly I:C-treated c-raf F/F (Fig. 11 B), c-rafΔliv/Δliv and  
c-rafΔhep/Δhep. These changes were reversible and regressed starting from 48 hours 
after DEN treatment as illustrated in Figure 11 C for c-raf F/F mice. Livers of Poly 
I:C-treated c-raf F/F, c-rafΔliv/Δliv, and c-rafΔhep/Δhep mice displayed similar DEN-
induced macroscopic changes. 
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Liver/body weight ratio is a parameter used to quantify changes in liver mass 
upon liver injury, in liver cancer and obesity studies, etc (Teoh et al. 2008; Bohm 
et al. 2010; Park et al. 2010). PolyI:C-treated c-raf F/F and c-rafΔliv/Δliv animals 
showed similar liver/body weight ratios, with values above 5% at 0h, 24h and 48h 
after DEN application (Fig. 12 A). Furthermore, no significant differences were 
observed between c-raf F/F and c-rafΔhep/Δhep at these time points (Maurer et al., un-
published data, not shown). PolyI:C-treated c-raf F/F and c-rafΔhep/Δhep littermates 
showed both lower liver/body weight ratios, with values around 4% (Fig. 12 B). 
The mice of this colony were usually 2 to 4 gram lighter than c-raf F/F and  
c-rafΔliv/Δliv animals of the same age and appeared more fragile. Further, c-rafΔhep/Δhep 
showed a tendency (not significant) towards a lower liver/body weight ratio 
(Maurer et al., unpublished data, not shown), possibly increasing after two Poly 
I:C injections, which are greatly challenging for these mice. The only significant 
difference between Poly I:C-treated c-raf F/F and c-rafΔhep/Δhep mice was observed 
48h after DEN, a time point which might be affected by the delay in the prolifera-
tive response (see below). 
Figure 11. Gross anatomy of Poly I:C and 
DEN-treated c-raf F/F livers. 
A) Poly I:C-treated c-raf F/F liver, normal healthy 
liver tissue with no macroscopic changes. B) Poly 
I:C-treated c-raf F/F liver 24h after DEN admini-
stration, clear spots all over the liver are clearly 
visible. C) Poly I:C-treated c-raf F/F 48h after 
DEN administration, damage starts to regress. 
Size bars indicate 1 cm. 
A B 
C 
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Figure 12. Liver/body weight ratio of poly I:C-treated c-raf F/F, c-rafΔliv/Δliv and c-rafΔhep/Δhep 
Mice measured 0h, 24h and 48h after DEN injection. 
A) Liver/body weight ratio of Poly I:C-treated c-raf F/F and c-rafΔliv/Δ average between 
5% and 6%, with no difference between knock out and wild type animals. Ratios are 
equal at time 0h and do not change within the observation period. B) The liver/body 
weight ratios of Poly I:C-treated c-raf F/F and c-rafΔhep/Δhep  mice showed no significant 
difference at 0h and 24h. although the ratios were slightly lower in c-rafΔhep/Δhep ani-
mals. This decreased ratio became significant 48h after DEN treatment. 
 
 
Hematoxylin and Eosin (H&E) staining of c-rafΔhep/Δhep livers revealed morpho-
logical changes around the central veins at 24h, in correspondence to the white 
spots observed macroscopically on livers after isolation. Hepatocytes in the 
pericentral area were bloated and showed a clear cell phenotype with translucent 
cytoplasm. These affected areas were lager in size in c-rafΔhep/Δhep mice when com-
pared to c-rafF/F littermates (Maurer et al., unpublished data, not shown). This 
difference could not be observed when c-rafΔliv/Δliv mice were compared with their 
Poly I:C-treated c-raf F/F littermates at 24h (Fig. 13 C-D), and morphological 
A 
B 
* 
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changes had (almost) disappeared at 48h in all genotypes (Fig. 13 E-F; and 
Maurer et al., unpublished data, not shown). A comparison of Poly I:C-treated  
c-rafF/F and c-rafΔhep/Δhep  littermates showed larger affected areas in the knock out  
livers 24h after DEN treatment (Fig. 13 G-H), indicating that Poly I:C had neither 
a positive nor a negative effect on the increased DEN-induced liver damage ob-
served by Maurer et al. in c-rafΔhep/Δhep livers. 
 
The enlarged affected areas observed in c-rafΔhep/Δhep were postulated to be con-
nected with enhanced susceptibility to tissue damage caused by DEN bioactiva-
tion around central veins. Liver injury and damage can be quantified via serum 
level measurement of two transaminases (aspartate aminotransferase – AST, and 
alanine aminotransferase – ALT). AST and ALT levels were determined for  
c-rafΔhep/Δhep and c-raf F/F littermates but showed no significant differences (Maurer 
et al., unpublished data, not shown), indicating that the origin of this difference 
lies somewhere else.  
 
A second possible cause for the enlarged affected areas is increased lipid accumu-
lation. DEN causes a disturbance in liver metabolism thereby inducing steatosis, 
which is an abnormal withholding of lipids in the liver and is known to be a pre-
disposing factor in human HCC (Park et al. 2010). Staining of lipid droplets on 
frozen liver tissue sections with Oil Red O, a fat-soluble dye, showed enhanced 
steatosis in c-rafΔhep/Δhep compared to c-raf F/F livers 24h and 48h after DEN-
treatment (Maurer et al., unpublished data, not shown). In contrast, DEN-induced 
lipid accumulation was similar in c-rafΔliv/Δliv and in their Poly I:C-treated c-raf F/F 
littermates at 0h, 24h and 48h (Fig. 14 A-F), Poly I:C-treated c-rafΔhep/Δhep animals 
displayed the same increased level of steatosis observed in c-rafΔhep/Δhep mice (Fig. 
14 G-H), ruling out that Poly:C treatment reduced DEN-induced liver damage and 
lipid accumulation in c-rafΔliv/Δliv animals. The lack of these phenotypes in  
c-rafΔliv/Δliv livers is therefore likely due to the influence of non-parenchymal cells, 
particularly Kupffer cells, which are c-raf knock out in these organs, and may 
react differently to acute liver damage.  
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Figure 13. H&E Staining of Liver Sections from Poly I:C-treated c-raf F/F, c-rafΔliv/Δliv and  
c-rafΔhep/Δhep Mice 0h, 24h and 48h after DEN-treatment. 
A – B) Poly I:C treated c-raf F/F (A) and c-rafΔliv/Δliv (B), displaying healthy liver tissue. 
C –D). Poly I:C-treated c-raf F/F (C) and c-rafΔliv/Δliv (D) 24h after DEN, showing mor-
phological changes around central veins including clear cell phenotype: the affected 
area, indicated by yellow circle has the same size in both genotypes. E – F) Poly I:C-
treated c-raf F/F (E) and c-rafΔliv/Δliv (F) isolated 48h after DEN treatment, showing re-
covery from liver injury; the clear cell phenotype has disappeared and normal liver 
morphology is restored. G – H) Poly I:C-treated c-raf F/F (G) and c-rafΔhep/Δhep (H) 24h 
after DEN injection, showing morphological changes similar to those in (C) and (D); 
however, the affected area (indicated by yellow circles) is larger in c-rafΔhep/Δhep than in 
their littermate controls. 
 
 
G H 
c-raf F/F c-rafΔhep/Δlhep 
- 43 - 
 
 
 
 
 
 
 
 
A B 
C D 
E F 
c-raf F/F c-rafΔliv/Δliv 
c-raf F/F c-rafΔliv/Δliv 
c-raf F/F c-rafΔliv/Δliv 
- 44 - 
 
 
 
 
 
 
Figure 14. Oil Red O Staining of Frozen Liver Sections from Poly I:C-treated c-raf F/F,  
c-rafΔliv/Δliv and c-rafΔhep/Δhep Mice 0h, 24h and 48h after DEN treatment. 
A – B) Poly I:C-treated c-raf F/F (A) and c-rafΔliv/Δliv (B) display normal liver tissue. C –
D). Poly I:C-treated c-raf F/F (C) and c-rafΔliv/Δliv (D) 24h after DEN treatment, showing 
lipid droplet accumulation around central veins, but no difference between the two 
genotypes. E – F) Poly I:C-treated c-raf F/F (E) and c-rafΔliv/Δliv (F) 48h after DEN 
treatment, showing normalization of the liver parenchyma. G – H) Poly I:C-treated  
c-raf F/F (G) and c-rafΔhep/ΔhepC (H) 24h after DEN, displaying steatosis as in (C) and 
(D). In this case lipid droplet accumulation is more evident in c-rafΔhep/Δhep mice than in 
their littermates. 
 
 
Cell death and apoptosis are tightly connected with tissue damage. DEN unfolds 
its cytotoxic property after bioactivation around the central veins, harming primar-
ily surrounding cells. Most apoptotic cells could be in fact detected around the 
central veins by TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end 
labeling) staining (Fig. 15 A). Statistical analysis did not show any significant 
difference between Poly I:C-treated c-rafΔliv/Δliv and c-rafF/F mice 0h, 24h and 48h 
after DEN (Fig. 15 B). Similar apoptotic indexes were also observed in  
c-rafΔhep/Δhep and their c-raf F/F littermates, untreated or treated with DEN for 24h 
and 48h (Maurer et al., unpublished data, not shown). Poly I:C-treated c-rafΔliv/Δliv 
and c-raf F/F displayed in general higher apoptotic indexes compared c-rafΔhep/Δhep 
G H 
c-raf F/F c-rafΔhep/Δhep 
- 45 - 
and c-raf F/F. This can be attributed to the Poly I:C application, since the c-raf F/F 
controls differ only in Poly I:C treatment and c-rafΔhep/Δhep and c-rafΔliv/Δliv animals 
are similar to their respective controls. This supports the hypothesis that Poly I:C 
may exert a ‘priming’ effect on the liver, leaving it in an post-inflammatory state, 
which allows a stronger and/or faster response to subsequent injury.  
 
 
 
Figure 15. Apoptosis in Poly I:C and DEN-treated c-raf F/F and c-rafΔliv/Δliv Mice. 
A) TUNEL staining of c-rafΔliv/Δliv liver tissue 24h after DEN treatment. Most apoptotic 
cells are observed around central veins, examples are indicated by black arrows. B) 
Statistical evaluation of TUNEL staining, showing no significant difference between 
Poly I:C-treated c-rafΔliv/Δliv and c-raf F/F mice. 
A B 
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IV.2 Inflammatory response of Poly I:C-treated c-raf F/F,  
c-rafΔliv/Δliv and c-rafΔhep/Δhep mice to DEN treatment 
 
As discussed in detail in the introduction, a cytokine-dependent (IL-6 and TNFα) 
and a growth factor dependent response (e.g. HGF) are activated upon liver injury 
to stimulate liver regeneration. The cytokine-dependent response mechanism in-
volves activation of STAT3 via phosphorylation (pSTAT3).  
 
STAT3 phosphorylation could be detected by immunohistochemistry in livers 24h 
and 48h after DEN application, and was much stronger in c-rafΔhep/Δhep mice than in 
c-raf F/F mice (Maurer et al., unpublished data, not shown). c-rafΔliv/Δliv mice 
showed inconsistent results, indicating in some cases stronger STAT3 activation, 
in some less and in others equal phosphorylation of STAT3 compared to Poly I:C-
treated c-raf F/F controls (Fig. 16 C-D). In contrast, STAT3 phosphorylation in 
Poly I:C-treated c-rafΔhep/Δhep was elevated compared to Poly I:C-treated c-raf F/F 
control mice 24h (Fig. 16 G-H) but not 48h after DEN. This shift in the kinetics of 
pSTAT3 signaling compared to c-rafΔhep/Δhep mice probably depends on the Poly 
I:C injections, which are triggering an additional inflammatory response, thus 
driving this pathway shortly before DEN application (7 days), and leaving perhaps 
a post-inflammatory state behind. Upon DEN challenge, poly I:C c-rafΔhep/Δhep liv-
ers might react faster but also ease quicker than their controls, re-setting STAT3 
activation back to c-raf F/F levels. 
 
Western blot analysis confirmed elevated levels of pSTAT3 in Poly I:C-treated  
c-rafΔhep/Δhep compared to Poly I:C-treated c-raf F/F littermates 24h after DEN (Fig. 
17). c-rafΔliv/Δliv mice showed inconsistent data concerning STAT3 activation, re-
flecting the picture provided by immunohistochemistry.  
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Figure 16. Immunohistochemistry of STAT3 Activation in Poly I:C-treated c-raf F/F,  
c-rafΔliv/Δliv and c-rafΔhep/Δhep livers after DEN treatment. 
A – B) Poly I:C-treated c-raf F/F (A) and c-rafΔliv/Δliv (B). STAT3 activation in liver tis-
sue is undetectable. C –D). Poly I:C-treated c-raf F/F (C) and c-rafΔliv/Δliv (D) 24h after 
DEN, showing some STAT3 activation throughout the tissue, but no difference be-
tween c-rafΔliv/Δliv and control organs. E – F) Poly I:C-treated c-raf F/F (E) and  
c-rafΔliv/Δliv (F) livers 48h after DEN treatment, showing decreased STAT 3 activation, 
the majority of pSTAT3 positive cells being part of the non-parenchymal compart-
ment. G – H) Poly I:C-treated c-raf F/F (G) and c-rafΔhep/Δhep (H) 24h after DEN treat-
ment, showing much higher STAT3 activation in Poly I:C treated c-rafΔhep/Δhep around 
portal veins. 
 
 
 
 
 pSTAT3  
 Tubulin  
Figure 17. Western blot Analysis of STAT3 Activation in Poly I:C-treated c-raf F/F, c-rafΔliv/Δliv 
and c-rafΔhep/Δhep liver lysates. 
A) pSTAT3 immunoblot of Poly I:C-treated c-raf F/F and c-rafΔliv/Δliv liver lysates pre-
pared 0h, 24h and 48h after DEN treatment. pSTAT3 levels correlate with those ob-
served by immunohistochemistry and show no significant differences between  
c-raf F/F and c-rafΔliv/Δliv animals. B) pSTAT3 immunoblot of Poly I:C-treated c-raf F/F 
and c-rafΔhep/Δhep liver lysates prepared 0h, 24h and 48h after DEN treatment. Stronger 
STAT3 activation is observed in c-rafΔhep/Δhep compared to c-raf F/F littermates 24h after 
DEN, in good correlation with the immunohistochemistry. 
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IL-6 is one of the triggers activating STAT3 phosphorylation, and since pSTAT3 
was elevated in c-rafΔhep/Δhep and Poly I:C-treated c-rafΔhep/Δhep compared to their  
c-raf F/F littermates, an elevation of IL-6 could likewise be expected. The amount 
of IL-6 was determined by ELISA in lysates from liver tissue and in blood serum 
of mice treated with DEN (Fig. 18 A-C). IL-6 levels in the liver lysates were un-
expectedly low and did not show any significant differences between Poly I:C-
treated c-rafΔhep/Δhep and c-raf F/F, between c-rafΔliv/Δliv and c-raf F/F, or between  
c-rafΔliv/Δliv and c-rafΔhep/Δhep mice . IL-6 levels were elevated in c-rafΔhep/Δhep com-
pared to c-rafF/F livers 6 hours after DEN treatment, but this effect had disap-
peared by 24h (Maurer et al., unpublished data, not shown). This indicates that  
IL-6 is expressed very early upon liver injury and that 24h and 48h after DEN 
treatment might be already too late to catch a difference between Poly I:C-treated 
c-rafΔliv/Δliv and c-rafΔhep/Δhep animals.  
 
Immunohistochemistry of Poly I:C-treated c-rafΔliv/Δliv and c-raf F/F liver sections 
confirmed the ELISA data, showing no difference in IL-6 expression 0h, 24h and 
48h after DEN. Localization of IL-6 in Poly I:C-treated c-rafΔliv/Δliv and c-raf F/F 
livers changed with treatment from pericentral to spread all over the tissue and 
back to central veins (Fig 19 A-F). This was at variance with c-rafΔhep/Δhep livers, 
where IL-6 staining was diffused at 0h but concentrated around central veins 6h 
after DEN treatment (Maurer et al., unpublished data, not shown), possibly indi-
cating a different production pattern in c-rafΔhep/Δhep and c-rafΔliv/Δliv livers. This is 
most likely due to the inflammatory state triggered by PolyI:C injections, since 
again the only difference between the c-raf F/F mice used as littermate controls is 
the Poly I:C treatment, and c-rafΔliv/Δliv as well as c-rafΔhep/Δhep animals behave simi-
larly to their controls. 
 
Serum IL-6 could only be detected in c-rafΔliv/Δliv mice 24h after DEN (Fig. 18 C). 
The levels were below detection in all other genotypes (Fig.18 C; and Maurer et 
al., unpublished data, not shown). This indicates a possible effect of non-
parenchymal cells c-raf on systemic IL-6 expression. 
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Figure 18. IL-6 ELISA from Poly I:C-treated c-raf F/F, c-rafΔliv/Δliv and c-rafΔhep/Δhep liver and 
serum samples collected after DEN injection. 
A) IL-6 levels in Poly I:C-treated c-raf F/F, in c-rafΔliv/Δliv livers and B)in Poly I:C-
treated c-raf F/F and c-rafΔhep/Δhep livers, which do not show any significant difference 
between the knock outs and littermate controls. C) IL-6 levels in blood serum of Poly 
I:C-treated c-raf F/F and c-rafΔliv/Δliv mice. IL-6 could be detected only in the serum of  
c-rafΔliv/Δliv treated with DEN for 24 hours. 
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Figure 19. IL-6 Immunohistochemistry on Poly I:C-treated c-raf F/F and c-rafΔliv/Δliv liver sec-
tions isolated 0h, 24h and 48h after DEN injection. 
A – B) Poly I:C-treated c-raf F/F (A) and c-rafΔliv/Δliv (B) livers with IL-6 expression 
around central veins. C –D). Poly I:C-treated c-raf F/F (C) and c-rafΔliv/Δliv (D) 24h after 
DEN treatment show diffused IL-6 staining throughout the tissue but no difference be-
tween c-raf F/F and c-rafΔliv/Δliv organs. E – F) Poly I:C-treated c-raf F/F (E) and c-rafΔliv/Δliv 
(F) 48h after DEN injection, showing IL-6 staining around the central veins.  
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IV.3 Post-DEN Regenerative Response in Poly I:C-treated  
c-raf F/F, c-rafΔliv/Δliv and c-rafΔhep/Δhep Mice 
 
The liver is an organ with a high regenerative capacity and reacts to injury with a 
proliferative response, thus replenishing the damaged cells which underwent 
apoptosis. In adult livers, proliferation is rarely observed except upon liver dam-
age. In this study, the age of the animals was approximately one month and mice 
were not adult yet, which explains the proliferation observed in Poly I:C-treated  
c-rafF/F and c-rafΔliv/Δliv livers prior to DEN treatment (Fig. 20 B). Proliferation 
drops upon DEN-mediated injury (24h) and a proliferative response starts at 48h 
in Poly I:C-treated c-raf F/F and c-rafΔliv/Δliv littermates (Fig. 20 B). Maurer et al. 
observed a delayed proliferation in DEN-treated c-rafΔhep/Δhep livers compared to  
c-raf F/F littermates at 48h, with a peak at 72h (unpublished data, not shown). Poly 
I:C-treated c-rafΔhep/Δhep mice also displayed this proliferative delay (Fig. 20 C), 
while c-rafΔliv/Δliv did not lag behind in proliferation at 24h and 48h when compared 
to Poly I:C-treated c-raf F/F littermates (Fig. 20 B). This indicates that Poly I:C did 
not influence this parameter, which is therefore a ‘real’ discriminator between  
c-raf ablation in hepatocytes and parenchymal/non-parenchymal cells. Proliferat-
ing cells were mainly observed in the periportal region (Fig. 20 A). These cells are 
believed to replace the cells undergoing apoptosis in the pericentral region, which 
are most susceptible to liver injury due to the DEN metabolization pattern. Hepa-
tocytes in c-rafΔhep/Δhep might be exposed to DEN for longer times or may accumu-
late more alterations in DNA compared to c-rafΔliv/Δliv or c-raf F/F, since these ani-
mals are able to respond to the liver injury by replacing the damaged parenchyma 
faster than the c-rafΔhep/Δhep mice. 
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Figure 20. Ki67 staining and 
quantification of proliferation in Poly I:C-
treated c-raf F/F, c-rafΔliv/Δliv and c-rafΔhep/Δhep 
Livers after DEN treatment. 
A) Ki67 staining of c-rafΔliv/Δliv liver tissue 
isolated 48h after DEN treatment. Most 
proliferating cells are observed around portal 
veins B) Statistical evaluation of Ki67 positive 
cells/mm2 tissue, showing the same levels of 
proliferation in Poly I:C-treated c-rafΔliv/Δliv and c-raf F/F littermates. C) Statistical evaluation of 
Ki67 positive cells of Poly I:C-treated c-rafΔhep/Δhep and c-raf F/F littermates. c-rafΔhep/Δhep mice show a 
proliferation delay at 48h when compared to c-raf F/F controls.  
 
 
A B 
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IV.4  Analysis of systemic inflammatory changes in DEN-
Treated Livers of Poly I:C-treated c-raf F/F, c-rafΔliv/Δliv 
and c-rafΔhep/Δhep Mice 
 
Analysis of blood samples (differential cell counts of lymphocytes, monocytes 
and granulocytes) showed no significant differences between Poly I:C-treated  
c-raf F/F, c-rafΔliv/Δliv and c-rafΔhep/Δhep mice 0h, 24h and 48h after DEN. All values 
were in the physiological range (Fig. 21 A-C). c-rafΔhep/Δhep blood samples showed 
similar values and were also in the physiological range (Maurer et al., unpublished 
data, not shown). This indicates that DEN treatment does not elicit acute systemic 
inflammation and neither does Poly I:C, since no differences between Poly I:C-
treated and untreated c-raf F/F were found (Maurer et al., unpublished data, not 
shown).  
 
 
 
 
 
 
 
 
Figure 21. WBC counts 
Number of lymphocytes (A), monocytes (B) and 
granulocytes (C) in the blood of Poly I:C-treated 
c-raf F/F, c-rafΔliv/Δliv and c-rafΔhep/Δhep mice 0h, 24h 
and 48h after DEN, showing physiological val-
ues.  
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V.  Discussion 
The development of hepatocellular carcinoma is a complex and yet not fully un-
derstood process involving numerous changes in hepatocytes resulting in altered 
proliferation, differentiation, apoptosis and genomic instability (Farazi and 
DePinho 2006). The ERK signaling cascade has been frequently implicated in 
HCC development (Whittaker et al. 2010) and C-Raf overexpression has been 
consistently observed in these tumors (Hwang et al. 2004; Hopfner et al. 2008). 
Despite its established role in activating MEK and thereby driving the ERK path-
way, C-Raf has distinct biological functions off this beaten track, including cross-
talking abilities with Rho signaling (Ehrenreiter et al. 2005; Piazzolla et al. 2005; 
Ehrenreiter et al. 2009) and with the two pro-apoptotic kinases ASK1 (Chen et al. 
2001; Yamaguchi et al. 2004) and MST2 (O'Neill et al. 2004; Matallanas et al. 
2007). Interestingly, these pathways have been shown to participate in liver car-
cinogenesis (Zender et al. 2006; Hui et al. 2008; Wong et al. 2008), bringing  
C-Raf with its cross-talking nature into the focus of interest as a possible thera-
peutic target in HCC treatment. 
 
Our results, so far, have revealed a surprising tumor suppressor function of C-Raf 
in chemically-induced hepatocarcinogenesis. Maurer et al. (unpublished data), 
could demonstrate enhanced tumor load and tumor multiplicity in mice with hepa-
tocyte-restricted c-raf ablation (c-rafΔhep/Δhep), which led to the hypothesis that c-raf 
suppressed tumor initiation. Concomitant deletion of c-raf in hepatocytes and he-
matopoietic-derived cells via the Mx-Cre system (c-rafΔliv/Δliv) rescued the pheno-
type (Maurer et al., unpublished data). This might mean that C-Raf plays opposite 
roles in DEN-induced liver damage, depending on the cell type in which it is ab-
lated. Alternatively, the Poly I:C treatment necessary for c-raf ablation in  
c-rafΔliv/Δliv mice may interfere with/neutralize the phenotype observed in  
c-rafΔhep/Δhep animals. In particular, Poly I:C treatment causes inflammation, which 
is a tumor promoter in this system. Indeed, Maurer et al. showed that DEN-
induced HCC development is accelerated in c-raf F/F mice treated with Poly I:C 
compared to c-raf F/F animals (unpublished data), suggesting a tumor-promoting 
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effect of Poly I:C in DEN-induced liver carcinogenesis. This study was designed 
to distinguish between these two hypotheses. In order to discriminate which of the 
differences observed in HCC development in c-rafΔliv/Δliv versus c-rafΔhep/Δhep mice 
are based on the ablation in different tissues, and which are due to Poly I:C side 
effects, we compared c-rafΔliv/Δliv with c-rafΔhep/Δhep animals treated with Poly I:C. 
 
DEN enters the liver via the portal vein, but becomes bioactivated around the cen-
tral veins, by the cytochrome P450 system, which is expressed by the hepatocytes 
in this area (Kang et al. 2007). Consequently, most of the damage happens in this 
pericentral region. Increased apoptosis was not observed in c-rafΔhep/Δhep mice after 
DEN treatment. This was particularly puzzling, since C-Raf is known to be crucial 
for the survival of hepatoblasts during embryonic development (Mikula et al. 
2001) and since it inhibits two pro-apoptotic kinases (Chen et al. 2001; O'Neill et 
al. 2004). However, four distinct consequences of hepatocyte-restricted c-raf abla-
tion could be identified in DEN-treated mice: larger damaged areas around the 
central veins, increased steatosis, increased and prolonged STAT3 signaling, and 
a delay in the compensatory proliferative response (Maurer et al., unpublished 
data).  
 
These phenotypes were not observed when c-raf was ablated in hepatocytes and 
non-parenchymal, hematopoietic cells. The area of damage, the degree of steatosis 
and STAT3 phosphorylation induced by DEN were similar in c-rafΔliv/Δliv mice and 
c-raf F/F littermates treated with Poly I:C. Furthermore, unlike the c-rafΔhep/Δhep 
animals, c-rafΔliv/Δliv mice did not show any delay in DEN-induced compensatory 
proliferation. The phenotypes observed in c-rafΔhep/Δhep mice could also be observed 
when these animals were injected with Poly I:C before DEN treatment; therefore, 
the different responses of c-rafΔhep/Δhep and c-rafΔliv/Δliv animals to DEN treatment are 
due to the distinct ablation patterns (hepatocyte-restricted ablation versus ablation 
in parenchymal and non-parenchymal cells). 
 
The increased DEN-induced liver damage observed in c-rafΔhep/Δhep animals com-
pared to their wild type controls is most likely associated with enhanced lipid 
droplet accumulation, since the damaged and steatotic areas overlapped remarka-
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bly  (Maurer et al., unpublished data). Steatosis is connected with liver injury and 
impaired regenerative response (Vetelainen et al. 2007) and could therefore nega-
tively affect the replacement of damaged hepatocytes, causing an increase in the 
pool of initiated cells. In line with this, proliferation was impaired in c-rafΔhep/Δhep 
mice (Maurer et al., unpublished data). By contrast, c-rafΔliv/Δliv mice were able to 
mount a normal compensatory proliferative response upon DEN-induced liver 
injury, and therefore efficiently replaced damaged cells with undamaged ones. In 
addition, steatosis has been shown to drive low-grade inflammation and to induce 
the release of inflammatory cytokines and hormones such as IL-1, IL-6, TNF-α, 
adiponectin and leptin by the adipose tissue and Kupffer cells (Park et al. 2010; 
Toffanin et al. 2010). Furthermore, steatosis was linked to the production of reac-
tive oxygen species (ROS), which induces persistent DNA damage and leads to 
genomic instability (Toffanin et al. 2010). ROS generation, a consequence of 
DEN metabolization and steatosis, (Maeda et al. 2005; Toffanin et al. 2010) was 
indeed increased in hepatocytes of DEN-treated c-rafΔhep/Δhep compared to c-raf F/F 
mice (Maurer et al., unpublished data). Persistent steatosis and ROS accumulation 
could sustain an inflammatory state and increase tumor development in  
c-rafΔhep/Δhep animals. This does not happen in c-rafΔliv/Δliv mice, which do not show 
any signs of steatosis or reduced compensatory proliferation. 
 
Inflammation is crucial for HCC development in humans and mice (Lin and Karin 
2007; Berasain et al. 2009). STAT3 activation, which is involved in the inflamma-
tory response after DEN-induced liver injury and further triggers the regenerative 
response, was stronger and more prolonged in c-rafΔhep/Δhep compared to c-raf F/F 
mice. This phenotype was not observed in c-rafΔliv/Δliv animals, suggesting that non-
parenchymal cells lacking c-raf are poor producers of STAT3 stimulating cytoki-
nes, or that pre-treatment with Poly I:C and the resulting cytokine production 
masked this phenotype. The latter hypothesis could be excluded since Poly I:C-
treated and untreated c-rafΔhep/Δhep displayed a comparable increase in DEN-
induced STAT3 activation. 
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In conclusion, steatosis, proliferation and STAT3 signaling could all be traced 
back to the different ablation pattern between c-rafΔhep/Δhep and c-rafΔliv/Δliv mice, 
excluding Poly I:C as an interfering factor in the c-rafΔliv/Δliv system. Therefore, the 
data are consistent with a requirement of C-Raf in non-parenchymal cells to sus-
tain increased tumorigenesis in c-rafΔhep/Δhep mice.  
 
Cytokines and growth factors produced by non-parenchymal cells, with Kupffer 
cells being a major source, will alter signaling pathways in hepatocytes. These 
pathways include the MAPK pathways ERK, JNK and p38, as well as the NF-κB 
pathway. Future studies will monitor the production of cytokines and growth fac-
tors associated with liver injury and regeneration (Fausto et al. 2006; Lin and 
Karin 2007) in c-rafΔhep/Δhep and c-rafΔliv/Δliv mice, and will compare this pattern with 
that obtained by stimulating Toll-like-receptors in cultured c-raf knockout hepato-
cytes. The data collected by monitoring IL-6 in our study suggest that cytokines 
are expressed and released very quickly, within hours after DEN treatment, and 
are back to basal values at 24h. Shorter time points after DEN administration (e.g. 
4h, 6h and 8h) might yield a better picture of cytokine expression in the injured 
liver. 
 
A final aspect to be considered is the possible effect of c-raf ablation on its two 
interacting pro-apoptotic kinases MST2 and ASK1. As detailed above, apoptosis 
was not altered in c-rafΔhep/Δhep and c-rafΔliv/Δliv compared to c-raf F/F and Poly I:C-
treated c-raf F/F littermates; still the MST2 signaling cascade is a negative regula-
tor of growth in general and of hepatocarcinogenesis in particular (Pan 2010) and 
ASK1 was described to be involved in stress response (Hattori et al. 2009). Thus, 
an investigation of these pathways is warranted. 
 
Finally, Maurer et al. observed that Poly I:C, which is needed for the activation of 
the Mx-promoter in c-rafΔliv/Δliv mice, accelerates DEN-induced carcinogenesis. 
Poly I:C application triggers an inflammatory response, thereby activating and 
additionally recruiting inflammatory cells to the liver, priming this organ and 
leaving behind a post-inflammatory state. Upon DEN-induced liver damage, ani-
mals pre-treated with Poly I:C (c-rafΔliv/Δliv and c-raf F/F littermates treated with 
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Poly I:C) displayed increased apoptosis compared to Poly I:C untreated mice  
(c-rafΔhep/Δhep and c-raf F/F mice). Cell damage and cell death in the liver can initiate 
the release of activating factors, stimulating particularly cells of the immune sys-
tem, like Kupffer cells, natural killer (NK) cells and NKT cells. These activated 
cells will produce pro-inflammatory cytokines such as TNF-α, Interferon (IFN)-γ 
and IL-1, thereby recruiting more inflammatory cells, driving liver injury further 
(Fig. 22) (Holt and Ju 2006). This sustained inflammatory environment could be 
causal for the increased carcinogenesis in PolyI:C treated livers. 
 
 
 
 
Figure 22. Drug-induced liver injury and its consequences, adapted from (Holt and Ju 2006) 
Proposed model of drug-induced liver damage, with non-parenchymal cells (Kupffer 
cells, NK and NKT cells) reacting to apoptotic signaling from surrounding cells, driv-
ing hepatoprotective and hepatotoxic pathways. The latter could be favored after Poly 
I:C treatment due to the post-inflammatory state left behind. 
 
In a nutshell, the information provided by this study in comparison with the un-
published data from Maurer et al. indicates at least two cell type-dependent roles 
for C-Raf in liver tumorigenesis (Fig 23): a role as a suppressor of chemically-
induced liver carcinogenesis in hepatocytes, and a tumor-promoting role in non-
parenchymal cells. In non-parenchymal cells C-Raf might be involved in cytokine 
expression, initiating an inflammation state with elevated STAT3 signaling in 
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knock out hepatocytes. This tumor-promoting effect is lost with c-raf ablation in 
non-parenchymal cells. Elucidating in depth the interplay between c-raf knockout 
hepatocytes and non-parenchymal cells, especially Kupffer cells, will be benefi-
cial for a better understanding and design of anti-cancer therapies, such as Soraf-
enib, targeting C-Raf among other molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Kupffer cell Hepatocyte 
Figure 23. Hypothesis of C-Raf Function in Drug-induced Liver carcinogenesis 
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VI.  Experimental Procedures 
 
VI.1 Animals and Treatment 
 
Animal Husbandry 
All mice used in this study were kept on a SV 129/SVHsd pure background. Male 
inbred mice were maintained in filter top cages at ambient room temperature (RT 
25°C), on autoclaved regular chow and autoclaved water, with a day/night cycle 
of 12h light and 12h dark under specific pathogen free (SPF) conditions, in the 
MFPL animal facility. 
 
Generation of conditional c-raf ko mice 
Mice (129/SVHsd) carrying loxP site flanked (floxed) exon 3 of the c-raf gene  
(c-raf F/F) were crossed to transgenic mice, expressing the Cre recombinase under 
the control of the albumin promoter and α-fetoprotein enhancer (Alfp-Cre) 
(Kellendonk et al. 2000) or under the control of the Mx promoter (Mx-Cre) (Kuhn 
et al. 1995). Cre activity of Alfp-Cre transgenic mice was detected between day 
9,5 post coitum (pc) and 10,5 pc (Kellendonk et al. 2000) thereby obtaining  
c-rafΔhep/Δhep animals. Mx-Cre mediated deletion of c-raf F/F was induced by two 
intraperitoneal (i.p.) injections of Poly (I:C) (Polyinosine-polycytidylic acid, Am-
ersham Biosciences Ref. #27-4732-01, 100µg in 50µl PBS) on day 18 and 21 to 
obtain c-rafΔliv/Δliv mice . As control c-raf F/F littermates treated with Poly I:C were 
used. 
 
c-rafΔhep/Δhep animals were analyzed by Maurer et al and were compared to  
c-rafΔliv/Δliv mice. As a control for possible Poly I:C effects c-rafΔhep/Δhep mice were 
treated with Poly I:C. Important to notice is that c-rafΔhep/Δhep have c-raf ablated in 
hepatocytes and need no Poly I:C for induction of Cre expression. 
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Figure 23. Conditional knock out and chemical induced carcinogenesis 
A) Mx-Cre knock out model with two Poly I:C injections on day 18 and 21 to induce 
Cre expression and obtain c-rafΔliv/Δliv; B) Cre expression in Alfp-Cre mice is detected 
around pc10 and gene ablation of c-raf in hepatocytes is completed around birth. Poly 
I:C is administered only as a control and is not needed for the induction of Cre expres-
sion. 
 
 
Administration of DEN 
4-week-old c-raf F/F, c-rafΔhep/Δhep and c-rafΔliv/Δliv male mice were injected i.p. with a 
single dose of DEN (Diethylnitrosamine, Sigma Ref. #N0258, 100mg/kg diluted 
in 0,9% NaCl, Sigma Ref. #S8776) (Fig. 23). Mice were killed by cervical dislo-
cation and liver samples were collected before DEN injection (0h time point) and 
at indicated time points after DEN injection (24h and 48h).  
A) 
B) 
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VI.2 Blood Analysis 
 
Blood (20 - 30 µL) was taken from tail vein and collected into EDTA coated 
MiniCollect tubes (Greiner Bio-One GmbH, Ref. #4500476). Whole blood analy-
sis was performed using the V-Sight Vet Hematology Analyzer (A. Menarini Di-
agnostics). Blood for serum analysis was collected by cardiac puncture after kill-
ing mice with CO2. Samples were left 30 min at RT for clotting and were centri-
fuged at 1.500 rounds per minute (rpm) for 10 min. Clear serum was collected, 
flash frozen in liquid nitrogen and stored at -80°C for further use. 
 
 
VI.3 DNA Methods  
 
Genomic DNA Preparation from Mouse Tissue 
Tissue samples were digested in 90µL Viagen DirectPCR-Tail (Peqlab Ref. #31-
102-T) + 10µL freshly added Proteinase K (10mg/mL, Sigma Ref. #P6556) o/n in 
a water bath at 55°C. After incubation, Proteinase K was inactivated by heating 
samples for 45 min at 85°C in a water bath. 
 
Mouse liver tissue (∼ 3-5 mm3) was digested in 200µL tail buffer incl. 10% 
freshly added Proteinase K (10mg/mL, Sigma Ref. #P6556) o/n in a water bath at 
55°C. On the next day, 100µL of saturated NaCl solution was added to the di-
gested liver tissue, mixed and centrifuged at 13.000 rpm at 4°C for 10 min. 200µL 
of supernatant were transferred to a fresh tube and the pellet was discarded. DNA 
was precipitated by adding 150µL of isopropanol, inverted gently several times, 
then shortly vortexed and centrifuged at 13.000 rpm at 4°C for 5 min. Supernatant 
was discarded, the pellet was washed once with cold 70% EtOH and centrifuged 
at 13.000 rpm at 4°C for 5 min. EtOH was discarded, pellet was air dried for 10 
min at 55°C on a thermo-mixer, dissolved in 50µL autoclaved water for 2 hours at 
55°C and stored at 4°C. DNA concentration was measured with Nanodrop (ND-
1000 Peqlab). 
 
Tail buffer: 50mM Tris-HCl pH8, 100mM EDTA pH8, 100 mM NaCl 
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PCR Genotyping 
Mouse toes and isolated livers were genotyped on a regular basis by polymerase-
chain-reaction (PCR) and realtime PCR. 
 
The c-raf genotype was analyzed by using the following PCR reaction mix: 
 
 Taq DNA Pol 2.0x Master Mix Red (Ampliqon, Ref.# 180306) 12,500 µl 
 Primer mpxr1 (100pM, VBC-Biotech) 0,125 µl 
 Primer mpxr2 (100pM, VBC-Biotech) 0,125 µl 
 Primer mpxr3D (100pM VBC-Biotech) 0,125 µl 
  ddH20 9,630 µl  
  DNA 2,000 µl (≈ 200ng) 
 Final Volume 24,500 µl 
c-raf primers 
mpxr1, 5’ TGT GCC CTT GGA ACC TCA GCA C-3’ 
mpxr2, 5’-ACA ACG AGA TAG ATG AGG AAA GCA-3’ 
mpxr3D, 5’CAC TGA AAT GAA AAC GTG AAG ACG-3’ 
 
PCR products: Primers mpxr1 and mpxr2 amplify a fragment of 280 base pairs 
(bp) when wt c-raf gene is present or 330 bp when c-raf gene is floxed; primers 
mpxr1 and mpxr3D amplify a fragment of 450 bp when c-raf gene is knocked out. 
 
PCR was performed by GeneAmp® PCR System 9700 with the following cycling 
protocol:  
 Initiation 98°C - 30sec 
 Denaturation 98°C - 10 sec 
 35 cycles Annealing 65°C - 30 sec 
 Elongation 72°C - 45 sec 
 Final Elongation 72°C - 1 min 
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The Cre recombinase transgene was detected by real-time PCR using the follow-
ing Cre realtime PCR mix: 
 
 Fermentas 10x Taq Buffer with KCl  2,00 µl 
  Fermentas 25 mM MgCl2 3,60 µl 
  Fermentas dNTPs Mix 10mM each 0,50 µl 
 CRE US (100pM, VBC-Biotech) 0,08 µl 
 CRE DS (100pM, VBC-Biotech) 0,08 µl 
 Cre Probe (1:10) 0,25 µl 
  Fermentas Taq DNA Polymerase (5u/µL) (Ref.# EP0402) 0,20 µl 
  H20 17,30 µl 
  DNA 2,00 µl 
 Final volume 26,00 µl 
 
Real-time PCR was performed using an iCycler (Bio-Rad) with the following 
cycling protocol:  
 
 Initiation 94°C 5 min 
 Denaturation 94°C 15 sec 
 Annealing and Elongation 57°C 45 sec 
 
Cre Primers  
CRE US, 5’-ATT CTC CCA CCG TCA GTA CG-3’ 
CRE DS, 5’-GCA TTT CTG GGG ATT GCT TA-3’ 
CRE Probe, 5’-Fam-AAC CCT GAT CCT GGC AAT TTC GGC-BHQ1-3’ 
PCR Product: 95bp fragment  
 
Agarose Gel Electrophoresis 
c-raf PCR products were directly loaded on a 2% Agarose gel (Agarose, Biozyme 
Ref. #840004, dissolved in TAE-buffer) supplemented with Ethidium bromide 
(5µL/100mL ). Electrophoresis was performed at 80-100 V for 30-50 min and the 
DNA was visualized under UV-light with Alpha-Imager (Alpha Innotech, 
Biozym).  
- 70 - 
VI.4 Histology 
 Liver Isolation, Tissue Fixation and Preparation of Paraffin embed-
ded Tissue Sections 
Livers were isolated, washed in cold PBS and dissected on ice. The large liver 
lobe was fixed in 4% Paraformaldehyde (PFA, Sigma, Ref. #P6148-1KG, diluted 
in PBS) overnight at 4°C. The next day the large liver lobe was transferred into 
70% ethanol, placed into an embedding cassette (Engelbrecht, Ref. #17980r) and 
processed in the Shandon Excelsior (Thermo Electron Corporation): 7x 1h of in-
creasing alcohol concentrations 70%-100%, 3x 1h Xylene and 3x 1h 20 min wax. 
Dehydrated tissue samples were embedded the following day in paraffin using an 
embedding center (Shandon Histocenter3 - Thermo Electron Corporation).  
Paraffin blocks were pre-cooled (-12°C) and 5 µm sections were cut (Leica RM 
2155) and transferred onto the surface of a 45°C warm water bath where the tissue 
could spread. Sections were transferred to Superfrost Plus slides (Gerhard Menzel 
GmbH Ref. #J1800AMNZ), dried at 45°C o/n and stored at RT until further use.  
 
 Hematoxylin-Eosin staining (H&E) 
H&E staining was performed with the staining assistant machine ASS-1 (Pathisto) 
by using the following protocol: 
 
1. Tissue Clear (Sanova, Ref. #SAK-1466) 10 
min 
2. Tissue Clear 10 min 
3. 100% EtOH 5 min 
4. 100% EtOH 5 min 
5. 90% EtOH 2 min 
6. 70% EtOH 2 min 
7. H2O 2 min 
8. Hematoxylin (Sigma Ref. #HHS32-1L) 6 min 
9. H2O 1 min 
10. 0,37% HCl/EtOH 5 sec 
11. H2O 10 min 
12. 70% EtOH 30 sec 
13. 80% EtOH 30 sec 
14. Eosin (Sigma, Ref. #HT110132-1L) 2 sec 
15. 90% EtOH 1 min 
16. 90% EtOH 1 min 
17. 100% EtOH 1 min 
18. 100% EtOH 1 min 
19. Tissue Clear 5 min 
20. Tissue Clear 5 min 
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H&E-stained sections were placed in Xylene (Sanova, Ref. #MKB-3410-1/1) for 10 
min and mounted with Entellan (Merck, Ref. #UN1866).  
 
 
 Immunohistochemistry – General Steps 
 
Deparaffinization and Rehydration  
The first step of each staining was to remove paraffin from the sections and to rehy-
drate the tissue: 
 
2x 10 min Xylene  
2x 10 min 100% EtOH 
2x 90 min 90% EtOH 
 
Slides were then transferred to ddH2O before proceeding with the next step. 
 
Blocking Endogenous Peroxidase Activity 
Slides were incubated for 10 min in peroxidase blocking solution (50-80% MeOH, 
1% H2O2) to avoid background signaling from endogenous peroxidases, washed 10x 
with H2O and left 5 min in ddH2O.  
 
Epitope Retrieval 
Depending on the antigen of interest different antigen retrieval methods where used to 
expose and preserve the desired epitopes: 
 
• Citrate buffer – Slides were placed in 10mM Tri-sodium-citrate-dehydrate-
buffer (Applichem, Ref. #2006753) pH 6 for 20-30 min at sub-boiling tem-
perature and cooled down at RT for 20 min. 
Antigen retrieval: Ki67  
• Proteinase K – Slides were incubated with Proteinase K (20µg/mL in 10mM 
Tris/HCl pH 7,4) for 15 min at 37°C. 
Antigen retrieval: TUNEL 
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• EDTA – Slides were incubated in 1mM Ethylenediaminetetraacetic acid solu-
tion (EDTA, Sigma Ref. #03680-1KG) pH 8 for 10-15 min at sub-boiling 
temperature. 
Antigen retrieval: pSTAT3 
• Trypsin/EDTA – Slides were incubated in 0,05% Trypsin-EDTA (PAA, Ref. 
#L11-003) in PBS for 12 min at 37°C. 
Antigen retrieval: IL-6 
 
Blocking Non-Specific Binding 
Slides were washed once with PBS for 5 min, transferred onto Shandon Coverplate™ 
(Thermo Scientific Ref. #72110017) and placed into a Shandon Sequenza rack 
(Thermo Scientific). 120µL of blocking solution (1,5% - 5% normal goat serum 
(NGS) in PBS or TBS-T) was applied on each section and incubated for 30 min to 1h 
in order to reduce background signaling resulting from unspecific binding.  
 
3.3’-Diaminobenzidine tretrahydrocholrid (DAB) reaction 
Slides were washed 3x 5 min with PBS, transferred into a staining jar and incubated 
with DAB solution for 7-8 min at RT. Tissue samples turned brown and sections were 
washed once with PBS for 5 min. 
 
DAB solution: 1 DAB tablet (Sigma Ref. #D5905-100TAB) in 50 ml 0,2M 
Tris/HCl pH 7,4 + 50µL H2O2 freshly added 
 
Counterstaining 
Sections were counterstained with filtered Hematoxylin (Sigma Ref. #HHS32-1L, 
diluted 1:10 in ddH2O) for 15-30 sec and washed 10 min under running tab water and 
5 min ddH2O.  
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Dehydration 
Sections were dehydrated by incubating the slides as following: 
 
2x 10 min 90% EtOH 
2x 10 min 100% EtOH 
2x 10 min Xylene 
 
Mounting 
Slides were mounted with Entellan (Merck, Ref. #UN1866). 
 
 
 Ki67 staining (proliferation) 
• Deparaffinization and Rehydration 
• Blocking endogenous peroxidase activity 
• Epitope retrieval: Citrate Buffer (25min, 97°C, cooling down for 20 min) 
• Blocking non-specific binding (1,5% NGS, 30 min) 
• Primary antibody – Ki67 polyclonal rabbit anti-mouse antibody (Novocastra 
Ref. #NCL-Ki67p), 1:1000 in PBS, 120µL/slide, o/n, 4°C. 
• Secondary antibody – Envision+ System-HRP Labelled Polymer Anti-Rabbit 
(Dako, Ref. #K4003).  
Slides were washed 3x 5 min with PBS between primary and secondary anti-
body. 3 drops of secondary antibody were applied per slide and incubated for 
30 min at RT.  
• DAB reaction 
• Counterstaining 
• Dehydration 
• Mounting 
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 In situ cell death detection kit, POD (Roche, Ref. #11684817910) – 
TUNEL assay 
• Deparaffinization and Rehydration 
• Blocking endogenous peroxidase blocking 
• Epitope retrieval Proteinase K (15 min, 37°C) 
• Positive control – selected section for positive control was treated 10 min with 
25 units DNase diluted in DNase buffer (Fermentas Ref. #EN0521) at RT and 
washed once with PBS for 5 min 
• Labelling – Sections were incubated with reaction mix (kit: 50µL from vial 1 
and 450µL from vial 2) 50µL/slide for 1h at 37°C in a humidified chamber. 
• Negative control – selected section for negative control was incubated with 
50µL from vial 2 (kit) for 1h at 37°C in a humidified chamber. 
• POD signal conversion – all sections were washed once with PBS for 5 min, 
incubated with POD converter (kit, 50µL/slide) for 30 min at 37°C in a hu-
midified chamber and washed again once with PBS for 5 min 
• DAB reaction 
• Counterstaining 
• Dehydration 
• Mounting 
 
 pSTAT3 staining 
• Deparaffinization and Rehydration 
• Blocking: endogenous peroxidase activity 
• Epitope retrieval EDTA (15min, 97°C) 
• Blocking Non-specific binding (5% NGS in TBS-T, 30 min) 
• Primary antibody – pSTAT3 (Tyr705) polyclonal rabbit antibody (Cell Signaling, 
Ref. #9145) 1:100 in 5% NGS in TBS-T, 120µL/slide, o/n, 4°C. 
• Secondary antibody – Envision+ System-HRP Labelled Polymer Anti-Rabbit 
(Dako Ref. #K4003).  
Slides were washed 3x 5 min with TBS-T and 2x 5 min with PBS in between 
primary and secondary antibody. 3 drops of secondary antibody were applied per 
slide and incubated for 30 min at RT.  
• DAB reaction 
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• Counterstaining 
• Dehydration 
• Mounting 
 
 
 IL-6 staining 
• Deparaffinization/Rehydration  
• Epitope retrieval: Trypsin-EDTA (12min, 37°C) 
• Blocking: endogenous peroxidase activity 
• Washing (2x 5 min TBS/0,0025% Triton X-100) 
• Blocking: non-specific binding (5% NGS in TBS, 1h) 
• Primary antibody – IL-6 polyclonal rabbit antibody (Abcam Ref. #ab6672) 1:200 
in 1% BSA in TBS, 120µL/slide, o/n, 4°C. 
• Secondary antibody – Envision+ System-HRP Labelled Polymer Anti-Rabbit 
(Dako Ref. #K4003).  
Slides were washed 3x 5 min with TBS-T and 2x 5 min with PBS between pri-
mary and secondary antibody. 3 drops of secondary antibody were applied per 
slide and incubated for 30 min at RT.  
• DAB reaction 
• Counterstaining 
• Dehydration 
• Mounting 
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 Preparation of O.C.T embedded tissue sections 
For cryo sections one smaller liver lobe was embedded into a Cryomold® (Sanova 
Ref. #4557) with O.C.T.™ compound (Sanova Ref. #4583) and flash frozen in liquid 
nitrogen. 7 µm thick sections were cut with a cryotome (Microm HM 500 OM), 
placed on Superfrost Plus slides (Gerhard Menzel GmbH Ref. #J1800AMNZ) and 
stored at -20°C. 
 
 Oil Red O staining (steatosis) 
Sections were air dried for 30 min at RT and fixed with 4% PFA for 10 min, then 
washed once in ddH2O for 5 min, incubated for 5 min in 60% isopropanol and incu-
bated further for 10 min in a 0,3% Oil Red O solution (Sigma, Ref. #O0625). Samples 
were dipped shortly in 60% isopropanol and ddH2O and counterstained with Hema-
toxylin, washed 10 min under running tap water and mounted with Glycerol (Merck, 
Ref. #ZC723095). Edges were sealed with commercially available nail polish. 
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VI.5 ELISA (Enzyme-linked immunosorbent assay) 
 
ELISA was performed by using a kit from R&D system (DuoSet® ELISA Develop-
ment System) and following the guidelines stated below: 
 
Capture Antibody: 96-well plate was coated with 100µl/well diluted capture 
antibody o/n. 
Blocking: 300µl/well blocking buffer was incubated for 2h.  
Standard and Samples: Serial dilution (1:2 – 1:32) of standard and serial dilution 
(1:100 – 1:3200) of 4 µg protein samples in Reagent Di-
luent were made, 100µL/well were applied and incubated 
for 2h. 
Detection antibody: 100µl/well diluted biotinylated detection antibody was in-
cubated for 2h. 
Streptavidin-HRP: 100µl/well diluted Streptavidin-HRP solution was incu-
bated for 20 min, protected from light. 
Substrate Reaction: 100µl/well substrate solution was incubated for 25 min, 
protected from light. Enzymatic substrate reaction was 
stopped with 50µl/well Stop solution. 
Results: Absorbance was measured using a microtiter plate reader 
at 450nm. The concentration of cytokine in the samples 
was calculated according to a standard curve, taking into 
consideration only the values in the linear range. 
 
All incubation steps were conducted at RT in a paraffin-sealed plate. Between steps, 
wells were washed three times with 400µL/well wash buffer (except before adding 
the stop solution). 
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Mouse IL-6 ELISA (R&D Systems, Ref. # DY406) 
Capture antibody: 2µg/ml (diluted in PBS) 
Standard: 1000pg/ml (diluted in Reagent Diluent) 
Wash buffer: 0,05% Tween20 in PBS, pH 7,2 – 7,4 
Blocking Buffer: 1% BSA in PBS, pH 7,2 – 7,4 
Reagent Diluent: 1% BSA in PBS, pH 7,2 – 7,4 
Streptavidin-HRP: 1:200 (diluted in Reagent Diluent) 
Substrate Solution: 1:1 color reagent A (H2O2) and color reagent B 
(Tetramethylbenzidine) 
Stop Solution: 2M H2SO4 
 
 
VI.6 Protein Methods 
 Protein Lysates from Mouse Liver Tissue 
Flash-frozen liver tissue samples (∼20-40 mg) were mixed with 200-400µL ice-cold 
RIPA Buffer including freshly added inhibitors (∼10µg tissue/µL RIPA Buffer) in a 
micro packaging vial (Peqlab, Ref. #91-PCS-TV) with 8 ceramic beads (Precellys-
Kermaik-Kügelchen, 1,4 mm Peqlab, Ref. #91-PCS-CK14B). For tissue homogeniza-
tion a Fast-Prep-24 machine (M.P. Biomedicals) was used: 2x 20 sec power 5. In be-
tween the two homogenization steps, samples were incubated for 2 min on ice. 
Lysates were centrifuged at 20.000g for 15 min at 4°C and the supernatants were 
transferred to a fresh tube, spun again at 20.000 g for 15 min at 4°C, supernatants 
transferred again to a fresh tube and immediately flash-frozen in liquid nitrogen. A 
small aliquot of the lysate was kept for protein concentration measurements (Bradford 
protein assay – see below). 
 
RIPA Buffer: 50 mM Tris HCl pH 8, 150mM NaCL, 1% TX-100, 0,5% 
Sodium Deoxycolate (added with inhibitors), 0,1% SDS, 
stored at 4°C in dark. 
 
Inhibitors (added freshly): 1mM PMSF, 2,5x Protease-Inhibitor Cocktail, 1mM 
Na3VO4, 100nM Okadaic acid 
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 Protein Concentration and Sample preparation 
Protein concentration of lysates was determined using the Bradford protein assay 
(Bio-Rad, Ref. #500-0006). Bradford solution was diluted 1:5 in ddH2O and 1ml was 
poured in each plastic cuvette. 5µL of sample or standard were added and incubated 
for 5 min before the absorbance was measured at 595nm with a spectrophotometer 
(U-2800A Hitachi). All measurements were done in duplicates or triplicates to avoid 
pipetting mistakes and 5µl of RIPA buffer was used as blank. 
 
Standard curve: Serial dilutions of BSA stock solution (100µg/µL) in RIPA 
buffer (3,6/2,9/2,3/1,65/1/0,5 µg/µl) were prepared and meas-
ured using the Bradford protein assay. 5µl of each standard di-
lution were incubated 5 min in 1mL of diluted Bradford solu-
tion before measurement. The standard curve was calculated 
on the basis of the absorption of each standard dilution. 
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Sample preparation: Concentration of lysates was calculated according to the stan-
dard curve described above and set to 2-5µg/µl (depending on 
the sample with the lowest concentration) by adding 5x sam-
ple buffer and β-Mercaptoethanol (10% of final vol.) and ad-
justing the volume with RIPA buffer. The samples were then 
boiled at 95°C for 10 min, centrifuged shortly and stored at -
20°C. 
 
5x sample buffer (for SDS-PAGE): 320mM Tris HCl, 5% SDS, 50% Glycerol, 
0,5% Bromphenol Blue; pH 6,8, stored at  
-20°C. 
 
 Sodium-Dodecyl-Sulphate-Polyachrylamide Gel  
Electrophoresis (SDS-PAGE) 
SDS gel apparatuses were cleaned, assembled and leakage was assessed with EtOH. 
Separating and stacking gel solutions were prepared according to the table below. 
Isopropanol was used to cover the polymerizing separating gel in order to ensure 
proper horizontal polymerization. After 20 to 30 min, the Isopropanol was removed 
and the stacking gel was poured on top of the separating gel. A comb with 10 slots for 
mini gels and 15 slots for midi gels was inserted and the stacking gel was left to po-
lymerize for 15 to 20 min. For electrophoresis, the gels were covered with 1x running 
buffer and samples were loaded with loading tips. Pre-stained protein ladder was used 
to determine the approximate protein size (PageRuler™ Fermentas Ref. # SM0671, 
10µl for mini gel, 20 µl for midi gel). Empty slots were filled with 10µl of 3x sample 
buffer to avoid any irregularities during the run. Electrophoresis was started with 50V 
and increased to 100V as soon as the samples entered the separating gel.  
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Separating gel mini gel (1,5 mm)midi gel (1,5 mm) 
 H20 4,0 ml 15,8 ml 
 30% Acrylamid 3,3 ml 13,3ml 
 1,5 M Tris pH 8,8 + 0,4% SDS 2,5 ml 10,0 ml 
 10% SDS 0,1 ml 0,4 ml 
 10% APS 0,1 ml 0,4 ml 
 TEMED (Tetramethylethylenediamine) 10,0 µl 20,0 µl 
 
Stacking gel mini gel (1,5 mm)midi gel (1,5 mm) 
 H20 2,80 ml 8,40 ml 
 30% Acrylamid 0,83 ml 2,50 ml 
 1,5 M Tris pH 6,8 + 0,4% SDS 1,50 ml 3,70 ml 
 10% SDS 0,05 ml 0,15 ml 
 10% APS 0,05 ml 0,15 ml 
 TEMED 5,00 µl 15,00 µl 
 
4x Separating buffer: 1,5 M Tris pH 8,8 + 0,4% SDS 
4x Stacking buffer: 0,5 M Tris pH 6,8 + 0,4% SDS 
10x Running buffer: 250mM Tris, 2,5M Glycine, 1% SDS 
Electrophoresis time: mini gel ∼2h-2,5h, midi gel ∼4h-4,5h 
 
 Western Blot 
After electrophoresis, the proteins were blotted onto a nitrocellulose membrane by 
two different methods: tank transfer and semidry transfer. 
 
Nitrocellulose membranes and Whatman® paper were cut to the approximate size of 
the gels and pre-wet in transfer buffer before assembly in BioRad Trans blot cell for 
tank transfer and BioRad Trans-blot Semidry transfer cell for semidry transfer. 
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 Cathode 
 2 Whatman® papers 
 gel 
 nitrocellulose membrane 
 2 Whatman® papers 
 Anode 
 
Air bubbles were removed by gently rolling a test tube on the top Whatman® papers.  
 
Semidry transfer (used for mini gels) 45 min 18V 
 
Wet transfer (used for midi gels) 1h 10V 
 o/n 30V 
 1h 50V 
 
Semidry transfer buffer: 48mM Tris pH 9,2, 39mM glycine, , 0,037%, 20% 
Methanol 
Wet transfer buffer: 25mM Tris pH 8,3, 250 mM glycine, 0,1% SDS, 10% 
Methanol 
Nitrocellulose membrane: Hybond™-C Extra Ref. # RPN303E 
 
Ponceau Red staining: Nitrocellulose membranes were placed in Ponceau Red 
solution (0,2% Ponceau S, 3% Trichloracetic acid) for 
one to two minutes and washed with ddH20 until protein 
bands became visible. Membranes were scanned and cut 
into strips aligning to the protein ladder. Finally, mem-
branes were washed 2x for 10 min with TBS-T to remove 
the remaining Ponceau Red in the membrane. 
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Immunolabeling: Nitrocellulose membranes were blocked for 1h in 5% 
milk (non fat milk, powder) in TBS-T, washed 3x with 
TBS-T for 10 min and incubated with 5-10 ml of primary 
antibody (see table below) overnight at 4°C rotating. On 
the next day, membranes were washed 3x with TBS-T for 
10 min and incubated with secondary antibody for 1h at 
RT gently shaking. Membranes were then washed 3x with 
TBS-T and developed using ECL system (see below). 
 
Antibodies: 
 
primary antibodies: Epitope Dilution Source MW (kDa) Company 
anti-c-Raf total protein 1:1000 B1 Rabbit, pc3 65 – 75  CS5 #9422 
anti-phospho-p44/42  Thr202/Tyr 204 1:1000 B1 Rabbit, pc3 42, 44 CS5 #9101 
MAP Kinase  
anti-posphoStat3 Tyr 705 1:1000 B1 Rabbit, mc4 79, 86 CS5 #9145 
anti-Tubulin total protein 1:10000 M2 Mouse, mc4 55 S-A6 T9026 
anti-YAP total protein 1:800 B1 Rabbit, pc3 65 – 75 CS5 #4912 
 
secondary antibodies:  Dilution Source  Company 
ECL™ anti-rabbit IgG HRP-linked 1:2000 M2 donkey GE Healthcare # NA934V 
ECL™ anti-mouse IgG HRP-linked 1:4000 M2 sheep GE Healthcare # NA931V 
 
1 B: diluted in 3% BSA in TBS-T 
2 M: diluted in 5% Milk (non-fat milk, powder) 
3 poly-clonal 
4 mono-clonal 
5 Cell Signaling Technology® 
6 Sigma- Aldrich Inc. 
 
ECL (Enhanced Chemi-Luminescent) reaction: After immunolabeling, nitrocellu-
lose membranes were incubated in SuperSignal® West 
Pico Chemiluminescent Substrate (Thermo Scientific, 
Ref. #34080) for 5 min. Chemiluminscence was detected 
using Amersham Hyperfilms™ ECL (GE Healthcare, Ref. 
#28906837) using diverse exposures times ranging from 1 
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sec to 30 min, depending on signal intensity. Films were 
developed using a Curix 60 processor (Agfa). 
 
 Membrane Stripping 
Stripping nitrocellulose membranes is the process by which secondary and primary 
antibodies are detached from the targeted epitopes. Stripping allows reprobing the 
membrane with antibodies detecting proteins of similar molecular weights, although 
loss of total protein amount needs to be taken into consideration. A mild stripping 
buffer was used for stripping membranes.  
 
Mild stripping buffer: 200mM Glycin, 200mM NaCl, pH 2,5, 3x 30 min at RT 
gently shacking and 3x 10 min washing with TBS-T. 
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VI.7 General Solutions and Reagents 
 
Loading buffer (6x): Bormphenolblue 0,25%, Xylene cyanol FF 0,25% 
Glycerol 50%, in H20 
PBS (Phosphate buffered saline): 137mM NaCL, 2,7mM KCl, 10mM Na2HPO4, 
1,76mM KH2PO4, pH7,4 
TAE (50x): 2M Tris, 1M Acetic acid, 0,05M EDTA pH 8 
TBS (Tris-Buffered Saline): 25mM, 150mM NaCl, pH 8. 
TBS-T (TBS-Tween 0,1%): 25mM, 150mM NaCl, pH 8, 0,01% Tween20 
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